US20130190383A1 - Nucleic acid compounds with conformationally restricted monomers and uses thereof - Google Patents

Abstract

This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA). The nucleic acid compounds are useful in various therapeutic modalities.

Description

TECHNICAL FIELD
• This disclosure relates generally to nucleic acid compounds for use in treating disease by regulating the expression of genes and other cell regulatory systems dependent upon a nucleic acid in a cell. More specifically, this disclosure relates to single-stranded and multi-stranded nucleic acid compounds having one or more duplex regions that can regulate the function or expression of nucleic acid molecules expressed in a cell. This disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). This disclosure further provides nucleic acid compounds containing one or more CRNs and one or more hydroxymethyl substituted nucleomonomers (UNA).
SEQUENCE LISTING
• This application includes a Sequence Listing submitted electronically herewith via EFS as an ASCII file created on Apr. 23, 2011, named MAR230PCT_SeqList_ST25_fin.txt, which is 126,128 bytes in size, and is hereby incorporated by reference in its entirety.
BACKGROUND
• RNA interference (RNAi) refers to the cellular process of sequence specific, post-transcriptional gene silencing in animals mediated by small inhibitory nucleic acid molecules, such as a double-stranded RNA (dsRNA) that is homologous to a portion of a targeted messenger RNA (Fire et al.,Nature391:806, 1998; Hamilton et al.,Science286:950-951, 1999). RNAi has been observed in a variety of organisms, including mammalians (Fire et al.,Nature391:806, 1998; Bahramian and Zarbl,Mol. Cell. Biol.19:274-283, 1999; Wianny and Goetz,Nature Cell Biol.2:70, 1999). RNAi can be induced by introducing an exogenous synthetic 21-nucleotide RNA duplex into cultured mammalian cells (Elbashir et al.,Nature411:494, 2001a).
• The mechanism by which dsRNA mediates targeted gene-silencing can be described as involving two steps. The first step involves degradation of long dsRNAs by a ribonuclease III-like enzyme, referred to as Dicer, into short interfering RNAs (siRNAs) having from 21 to 23 nucleotides with double-stranded regions of about 19 base pairs and a two nucleotide, generally, overhang at each 3′-end (Berstein et al.,Nature409:363, 2001; Elbashir et al.,Genes Dev.15:188, 2001b; and Kim et al.,Nature Biotech.23:222, 2005). The second step of RNAi gene-silencing involves activation of a multi-component nuclease having one strand (guide or antisense strand) from the siRNA and an Argonaute protein to form an RNA-induced silencing complex (“RISC”) (Elbashir et al.,Genes Dev.15:188, 2001). Argonaute initially associates with a double-stranded siRNA and then endonucleolytically cleaves the non-incorporated strand (passenger or sense strand) to facilitate its release due to resulting thermodynamic instability of the cleaved duplex (Leuschner et al.,EMBO7:314, 2006). The guide strand in the activated RISC binds to a complementary target mRNA, which is then cleaved by the RISC to promote gene silencing. Cleavage of the target RNA occurs in the middle of the target region that is complementary to the guide strand (Elbashir et al., 2001b).
• What is needed are alternative effective therapeutic modalities useful for treating or preventing diseases or disorders by regulating the expression of genes and other nucleic acid based regulatory systems in a cell.
• A need therefore exists for nucleic acid compounds having enhanced stability that are useful in various therapeutic modalities such as RNA interference.
BRIEF SUMMARY
• This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that can regulate the function or expression of nucleic acid molecules expressed in a cell and/or cell regulatory system dependent upon a nucleic acid in a cell. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). In some embodiments, a nucleic acid compound may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA).
• In some embodiments, this disclosure provides a range of nucleic acid compound comprising a first strand having from 10 to 60 nucleomonomers, wherein from 1 to 45 of the nucleomonomers of the first strand are the same or different conformationally restricted nucleomonomers each independently selected from
• Monomer R having the formula:
• 
• • wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂;
  • R₂and R₃are phosphodiester linkages of the nucleic acid compound; and
  • B is a nucleobase or nucleobase analog; and
• Monomer Q having the formula:
• 
• • wherein X and Y are independently for each occurrence selected from O, S, CH₂; C═O, C═S, C═CH₂, CHF, CF₂;
  • Z is independently for each occurrence selected from N or CH;
  • R₂is independently for each occurrence selected from hydrogen, —F, —OH, —OCH₃, —OCH₃OCH₃, —OCH₂CH₃OCH₃, —CH₂CH₃OCH₃, —CH(OCH₃)CH₃, and allyl;
  • R₁and R₃are phosphodiester linkages of the nucleic acid compound; and
  • B is a nucleobase or nucleobase analog;
    wherein each nucleobase or nucleobase analog in the strand is independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O⁶-methylguanine, N⁶-methyladenine, O⁴-methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and any existing deoxy analogs of the foregoing.
• A compound of this disclosure may contain two or more of the same or different Monomer R. In some embodiments, a compound may contain two or more of the same or different Monomer Q. In certain embodiments, the first strand may have from 19 to 27 nucleomonomers. In some aspects, the compounds of this disclosure RNA, or RNA and DNA.
• In certain aspects, a compound of this disclosure may include one or more hydroxymethyl substituted nucleomonomers.
• This disclosure further provides a range of compounds having one or two additional strands each having from 7 to 60 nucleomonomers, wherein at least a portion of each of the additional strands is complementary to a portion of the first strand, wherein the first strand and the one or two additional complementary strands can anneal to form one or more duplex portions having a total of from 8 to 60 base pairs in the duplex portions, and wherein one or more of the nucleomonomers of the one or two additional strands is a conformationally restricted nucleomonomer.
• A compound of this disclosure may have a sequence targeted for various genes. In some embodiments, a compound of this disclosure may have a sequence targeted for PLK1, a sequence targeted for Survivin BIRCS, a sequence targeted for Factor VII, or a sequence targeted for ApoB.
• In certain embodiments, a compound of this disclosure may have conformationally restricted nucleomonomers only present in either of the one or more additional strands, and the first strand does not contain any conformationally restricted nucleomonomers.
• In further embodiments, a compound may have a melting temperature increased by at least 1° C. over the same compound that does not contain any conformationally restricted nucleomonomers.
• Some compounds of this disclosure are siRNAs, or mdRNAs, or RNA and DNA. In certain embodiments, a compound may have one of the additional strands having one or more nicks. A compound may have one or more duplex gaps that are each independently from 1 to 10 unpaired nucleomonomers in length. A compound may have a blunt end. A compound may have a 3′-end overhang.
• This disclosure further contemplates compounds for use in delivering an RNA agent into a cell or an organism. A compound may be used in mediating nucleic acid modification of a target nucleic acid in a cell or an organism. A compound may be used use in decreasing expression levels of a target mRNA in a cell or an organism.
• In some embodiments, a compound may be used in inhibiting an endogenous nucleic acid-based regulatory system in a cell or an organism.
• In further embodiments, a compound may be used in gene regulation, gene analysis, or RNA interference.
• In some aspects, a compound may be used in the manufacture of a medicament for a therapeutic target, including targets for cancers, metabolic diseases, inflammatory diseases, and viral infections.
• In certain aspects, a compound may be used in treating a disease, condition or disorder, including cancers, metabolic diseases, inflammatory diseases, and viral infections.
• In further aspects, this disclosure contemplates methods for treating a disease, condition or disorder in a subject including cancers, metabolic diseases, inflammatory diseases, and viral infections, the method comprising administering to the subject a compound according to any one of claims1-23.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1: Example nucleic compounds containing one or more hydroxymethyl substituted nucleomonomer (represented by an “O” in the nucleic acid compound) and/or a conformationally restricted nucleomonomer (represented by a “⋄” in the nucleic acid compound).FIG. 1A is a double-stranded nucleic acid compound. The nucleic acid compounds ofFIG. 1B have the same configuration as the nucleic acid compound ofFIG. 1A, but each has two conformationally restricted nucleomonomers.FIG. 1C shows two nucleic acid compounds having equal length antisense and sense strands, each from 10 to 17 nucleomonomers in length.FIG. 1D is a nucleic acid compound complex having a nicked or gapped sense strand and a continuous antisense strand.FIG. 1E is a single-stranded nucleic acid compound having from 10 to 40 nucleomonomers.FIG. 1F is a single-stranded nucleic acid compound having from 10 to 40 nucleomonomers. The middle region noted as white represents from 4 to 8 deoxynucleotides, and the solid black regions at the 5′-end and 3′-end of the compound are ribonucleotides.
• FIG. 2: Examples of conformationally restricted nucleoside analogs that may be incorporated or substituted into nucleic acid compounds.
• FIG. 3: Dimers A and B represents possible backbone linkages between two Q Monomers.
• FIG. 4: Monomers A, B, C and D are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds.
• FIG. 5: Monomers E, F, G and H are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds.
• FIG. 6: Monomers I, J, K and L are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds.
• FIG. 7: Monomers M, N, O and P are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds.
DETAILED DESCRIPTION
• This disclosure relates generally to nucleic acid compounds for use in treating disease by gene silencing or modulating the function of a cell regulatory system dependent upon a nucleic acid in a cell and, more specifically, to nucleic acid compounds comprising a single strand of nucleomonomers or double-stranded nucleic acid compound comprising an antisense strand and a continuous or a discontinuous passenger strand, i.e., “sense strand” containing a nick or gap, that decreases expression of a target gene, and to uses of such nucleic acid compound to treat, prevent or manage a disease or condition associated with inappropriate expression of a nucleic acid.
• The nuclei acid compounds of this disclosure may further contain one or more conformationally restricted nucleomonomers (CRN) which advantageously enhance the stability of the compound in various therapeutic modalities.
• In some embodiments, a nucleic acid compound may contain one or more CRNs and one or more hydroxymethyl substituted nucleomonomers (UNA).
• The structures of a range of compounds of this invention are shown inFIG. 1. Example nucleic compounds containing one or more hydroxymethyl substituted nucleomonomers, represented by an “O” in the nucleic acid compound, and/or a conformationally restricted nucleomonomer, represented by a “⋄” in the nucleic acid compound.FIG. 1A is a double-stranded nucleic acid compound (e.g., double-stranded RNA (dsRNA) complex) with an antisense strand (bottom strand) and sense strand (top strand) of equal length (e.g., from 18 to 40 nucleomonomers in length) having two hydroxymethyl substituted nucleomonomers at the 3′-end of the sense strand and one hydroxymethyl substituted nucleomonomer at the 5′-end of the sense strand, and two hydroxymethyl substituted nucleomonomers at the 3′-end of the antisense strand. A hydroxymethyl substituted nucleomonomer may also be in the antisense strand of the duplex region. The nucleic acid compounds ofFIG. 1B have the same configuration as the nucleic acid compound ofFIG. 1A, but each has two conformationally restricted nucleomonomers. In one example, the two conformationally restricted nucleomonomer are in the antisense strand of the duplex region, and in another example, the two conformationally restricted nucleomonomer are in the sense strand of the duplex region.FIG. 1C shows two nucleic acid compounds (double-stranded) having the same modifications as the two nucleic acid compounds ofFIG. 1B, but for these two examples, the equal length antisense and sense strands of each are from 10 to 17 nucleomonomers in length.FIG. 1D is a nucleic acid compound complex having a nicked or gapped sense strand (top strand) having two conformationally restricted nucleomonomers that flank the nick or gap in the sense strand (each of the two double-stranded regions of the nucleic acid compound have a conformationally restricted nucleomonomer), and a continuous antisense strand. The two double-stranded regions of the nucleic acid compound are each from 7 to 20 base pairs. The nucleic acid compound has two 3′-end overhangs.FIG. 1E is a single-stranded nucleic acid compound having from 10 to 40 nucleomonomers and six conformationally restricted nucleomonomers.FIG. 1F is a single-stranded nucleic acid compound having from 10 to 40 nucleomonomers. The middle region (noted as white) represents from 4 to 8 deoxynucleotides, and the solid black regions at the 5′-end and 3′-end of the compound are ribonucleotides, each solid black region has two conformationally restricted nucleomonomers.
• Some conformationally restricted nucleomonomers and nucleic acid compounds comprising conformationally restricted nucleomonomers may be found in U.S. Pat. Nos. 6,833,361; 6,403,566 and 6,083,482, each of which is hereby incorporated by reference in its entirety.
• In one aspect, this disclosure provides a nucleic acid compound comprising a first strand having from 10 to 60 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) nucleomonomers, wherein one or more of the nucleomonomers is a conformationally restricted nucleomonomer.
• In some embodiments, this disclosure provides a nucleic acid compound comprising a first strand having from 10 to 40 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40) nucleomonomers, wherein one or more of the nucleomonomers is a conformationally restricted nucleomonomer.
• In certain embodiments, the melting temperature of the nucleic acid compound is from 40° C. to 100° C., or from 60° C. to 90° C., or from 75° C. to 80° C.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 40% to 50% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises RNA. In certain embodiments, the nucleic acid compound comprises DNA. In certain embodiments, the nucleic acid compound comprises RNA and DNA.
• In other embodiments, the first strand is from 10 to 30 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) nucleomonomers in length.
• Examples of conformationally restricted nucleoside analogs that may be incorporated or substituted into nucleic acid compounds are shown inFIG. 2. Monomer Q contains a C3′-C5′ bridge. Monomer R contains a C2′-C4′ bridge. For Monomers Q and R, X may be an —O—, —S—, —CH₂, C═O, C═S, C═CH₂, CHF or CF₂; Z may be an N or CH; R₂may be —H, —OH, —O-alkyl, —F, —SH, —S-alkyl, —S—F, —NH(CH═O), —NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• Dimers A and B shown inFIG. 3 represent possible backbone linkages between two Q Monomers. For Dimers A and B, Z₂and Z₃may be O, S, CO, P(O), P(O)R, P(O)O, CH₂; Ri and R₃may be OH, NH, NH2, DMTO, TBDMSO, OP(OR)N(iPr)₂, OP(OR)(O)H; and R may be methyl or 2-cyanoethyl.
• Embodiments of this invention include a nucleic acid compound comprising a first strand having from 10 to 60 nucleomonomers, wherein from 1 to 45 of the nucleomonomers of the first strand are the same or different conformationally restricted nucleomonomers each independently selected from
• Monomer R having the formula:
• 
• • wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂;
  • R₂and R₃are phosphodiester linkages of the nucleic acid compound; and
  • B is a nucleobase or nucleobase analog; and
• Monomer Q having the formula:
• 
• • wherein X and Y are independently for each occurrence selected from O, S, CH₂; C═O, C═S, C═CH₂, CHF, CF₂;
  • Z is independently for each occurrence selected from N or CH;
  • R₂is independently for each occurrence selected from hydrogen, —F, —OH, —OCH₃, —OCH₃OCH₃, —OCH₂CH₃OCH₃, —CH₂CH₃OCH₃, —CH(OCH₃)CH₃, allyl;
  • R₁and R₃are phosphodiester linkages of the nucleic acid compound; and
  • B is a nucleobase or nucleobase analog;
    wherein each nucleobase or nucleobase analog in the strand is independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O⁶-methylguanine, N⁶-methyladenine, O⁴-methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and any existing deoxy analogs of the foregoing.
• The compound above, wherein the compound contains two or more of the same or different Monomer R.
• The compound above, wherein the compound contains two or more of the same or different Monomer Q.
• The compound above, wherein the first strand has from 19 to 27 nucleomonomers.
• The compound above, wherein the nucleic acid is RNA.
• The compound above, wherein the nucleic acid is RNA and DNA.
• The compound above, further comprising one or more hydroxymethyl substituted nucleomonomers.
• The compound above, further comprising one or two additional strands each having from 7 to 60 nucleomonomers, wherein at least a portion of each of the additional strands is complementary to a portion of the first strand, wherein the first strand and the one or two additional complementary strands can anneal to form one or more duplex portions having a total of from 8 to 60 base pairs in the duplex portions, and wherein one or more of the nucleomonomers of the one or two additional strands is a conformationally restricted nucleomonomer.
• The compound above, wherein any one or more of the strands has a sequence for PLK1 selected from SEQ ID NOs:161-220.
• The compound above, wherein any one or more of the strands has a sequence for Survivin BIRCS selected from SEQ ID NOs:1-160.
• The compound above, wherein any one or more of the strands has a sequence for Factor VII selected from SEQ ID NOs:474-495.
• The compound above, wherein any one or more of the strands has a sequence for ApoB selected from SEQ ID NOs:496-507.
• The compound above, wherein any one or more of the strands has a sequence selected from SEQ ID NOs:221-230, 231-245, 246-255, 256-265, 266-275, 276-285, 286-295, 296-305, 306-315, 316-325, 326-335, 336-345, 346-355, 356-365, 366-375, 376-385, 386-395, 396-405, 406-415, 416-425, 426-435, 436-445, 446-455, 456-465, 508-517, and 518-527.
• The compound above, wherein the conformationally restricted nucleomonomers are only present in either of the one or more additional strands, and the first strand does not contain any conformationally restricted nucleomonomers.
• The compound above, wherein the melting temperature of the compound is increased by at least 1° C. over the same compound that does not contain any conformationally restricted nucleomonomers.
• The compound above, wherein the compound is an siRNA.
• The compound above, wherein the compound is an mdRNA.
• The compound above, wherein the compound is RNA and DNA.
• The compound above, wherein one of the additional strands has one or more nicks.
• The compound above, wherein the compound has one or more duplex gaps that are each independently from 1 to 10 unpaired nucleomonomers in length.
• The compound above, wherein the compound has a blunt end.
• The compound above, wherein the compound has a 3′-end overhang.
• The compound above, further comprising one or more hydroxymethyl substituted nucleomonomers.
• The compound above for use in delivering an RNA agent into a cell or an organism.
• The compound above for use in mediating nucleic acid modification of a target nucleic acid in a cell or an organism.
• The compound above for use in decreasing expression levels of a target mRNA in a cell or an organism.
• The compound above for use in inhibiting an endogenous nucleic acid-based regulatory system in a cell or an organism.
• The compound above for use in gene regulation, gene analysis, or RNA interference.
• The compound above for use in the manufacture of a medicament for a therapeutic target, including targets for cancers, metabolic diseases, inflammatory diseases, and viral infections.
• The compound above for use in treating a disease, condition or disorder, including cancers, metabolic diseases, inflammatory diseases, and viral infections.
• A method for treating a disease, condition or disorder in a subject including cancers, metabolic diseases, inflammatory diseases, and viral infections, the method comprising administering to the subject a compound above.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• where X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• where X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OCH₃; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more Monomer R and one or more Monomer Q.
• In some embodiments, B represents a nucleobase or nucleobase analog independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O⁶-methylguanine, N⁶-methyladenine, O⁴-methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and any existing deoxy analogs of the foregoing.
• In some embodiments, B represents a nucleobase or nucleobase analog independently selected from adenine, cytosine, guanine, uracil, and any existing deoxy analogs of the foregoing.
• In certain embodiments, the nucleic acid compound further comprises a second strand.
• Monomers A, B, C and D shown inFIG. 4 are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds. Monomer B is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the Cr atom of the acyclic ribose-based scaffold) of Monomer A, and Monomer D is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the Cr atom of the acyclic-ribose-based scaffold) of Monomer C. Monomers A and B are the D-isoform of an acyclic-ribose-based scaffold, and Monomers C and D are the L-isoform of an acyclic-ribose-based scaffold. For Monomers A and C, X may be an —O—, —S—, or —CH₂; Z may be an —H, —OH, —CH₂OH, —CH₃or saturated or unsaturated C(2-22) alkyl chain; J may be P or S; R₂may be —H, —OH, —O-alkyl, —F, —SH, —S-alkyl, —S—F, —NH(CH═O), —NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• Monomers E, F, G and H shown inFIG. 5 are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds. Monomer F is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the C4′ atom of the acyclic ribose-based scaffold) of Monomer E, and Monomer H is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the C4′ atom of the acyclic ribose-based scaffold) of Monomer G. Monomers E and F are the D-isoform of an acyclic-ribose-based scaffold, and Monomers C and D are the L-isoform of an acyclic ribose-based scaffold. For Monomers E and G, X may be an —O—, —S—, or —CH₂; Z may be an —H, —OH, —CH₂OH, —CH₃or saturated or unsaturated C(2-22) alkyl chain; J may be P or S; R₂may be —H, —OH, —O-alkyl, —F, —SH, —S-alkyl, —S—F, —NH(CH═O), —NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• Monomers I, J, K and L shown inFIG. 6 are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds. Monomer J is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the Cr atom of the acyclic ribose-based scaffold) of Monomer I, and Monomer L is an exemplary hydroxymethyl substituted nucleomonomer (the hydroxymethyl group is attached at the Cr atom of the acyclic ribose-based scaffold) of Monomer K. Monomers I and J are the D-isoform of an acyclic-ribose-based scaffold, and Monomers K and L are the L-isoform of an acyclic ribose-based scaffold. For Monomers I and K, X may be an —O—, —S—, or —CH₂; Z may be an —H, —OH, —CH₂OH, —CH₃or saturated or unsaturated C(2-22) alkyl chain; J may be P or S; R₂may be —H, —OH, —O-alkyl, —F, —SH, —S-alkyl, —S—F, —NH(CH═O), —NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• Monomers M, N, O and P shown inFIG. 7 are acyclic non-nucleotide monomers that may be incorporated into nucleic acid compounds. Monomer N is an exemplary hydroxymethyl substituted nucleomonomer (two hydroxymethyl groups are attached at the C4′ atom of the acyclic ribose-based scaffold) of Monomer M, and Monomer P is an exemplary hydroxymethyl substituted nucleomonomer (two hydroxymethyl groups are attached at the C4′ atom of the acyclic ribose-based scaffold) of Monomer 0. Monomers M and N are the D-isoform of an acyclic-ribose-based scaffold, and Monomers 0 and P are the L-isoform of an acyclic ribose-based scaffold. For Monomers M and O, X may be an —O—, —S—, or —CH₂; Z may be an —H, —OH, —CH₂OH, —CH₃or saturated or unsaturated C(2-22) alkyl chain; J may be P or S; R₂may be —H, —OH, —O-alkyl, —F, —SH, —S-alkyl, —S—F, —NH(CH═O), —NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• Some hydroxymethyl substituted nucleomonomers and nucleic acid compounds comprising hydroxymethyl substituted nucleomonomers may be synthesised using phosphoramidite derivatives using the standard techniques for nucleic acid synthesis. Some methods for synthesis of hydroxymethyl substituted nucleomonomers and hydroxymethyl substituted nucleic acid compounds may be found in PCT International Application PCT/US2008/064417, which is hereby incorporated by reference in its entirety.
• In certain embodiments, the nucleic acid compound comprises a hydroxymethyl substituted nucleomonomer. In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In another aspect, the instant disclosure provides a nucleic acid compound comprising a first strand having from 10 to 60 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) nucleomonomers, and a second strand complementary to the first strand, wherein the first strand and the second strand can anneal to form 8 to 60 (or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) base pairs, and wherein one or more of the nucleomonomers of the first strand or the second strand is a conformationally restricted nucleomonomer.
• In certain embodiments, the melting temperature of the nucleic acid compound is from 40° C. to 100° C., or from 60° C. to 90° C., or from 75° C. to 80° C.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or wherein from 40% to 50% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, the first strand is from 10 to 40 nucleomonomers in length. In other embodiments, the first strand is from 15 to 35 nucleomonomers in length. In yet other embodiments, the first strand is from 18 to 30 nucleomonomers in length. In yet other embodiments, the first strand is from 19 to 23 nucleomonomers in length. In yet another embodiment, the first strand is from 25 to 30 nucleomonomers in length.
• In certain embodiments, the second strand is from 8 to 60 nucleomonomers in length. In other embodiments, the second strand is from 10 to 40 nucleomonomers in length. In yet other embodiments, the second strand is from 15 to 35 nucleomonomers in length. In yet other embodiments, the second strand is from 18 to 30 nucleomonomers in length. In yet other embodiments, the second strand is from 19 to 23 nucleomonomers in length. In yet another embodiment, the second strand is from 25 to 30 nucleomonomers in length.
• In certain embodiments, any one or more of the last 15 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, any one or more of the last 10 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, two or more of the last 15 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, two or more of the last 10 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, three or more of the last 15 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, three or more of the last 10 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, four or more of the last 15 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, four or more of the last 10 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, five or more of the last 15 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, five or more of the last 10 positions at the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiment, any one or more of the last 15 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiment, any one or more of the last 10 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, two or more of the last 15 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, two or more of the last 10 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, three or more of the last 15 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, three or more of the last 10 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, four or more of the last 15 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, four or more of the last 10 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, five or more of the last 15 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, five or more of the last 10 positions at the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, the nucleic acid compound comprises RNA. In certain embodiments, the nucleic acid compound comprises DNA. In certain embodiments, the nucleic acid compound comprises RNA and DNA.
• In certain embodiments, the nucleic acid compound is an siRNA.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• where X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• where X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OCH₃; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more Monomer R and one or more Monomer Q.
• In certain embodiments, the first and second strands are a contiguous strand of nucleomonomers. In certain embodiments, the second strand has one or more nicks. In certain embodiments, the second strand has one or more gaps. In a related embodiment, the one or more gaps, independently for each occurrence, comprise from 1 to 10 (or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) unpaired nucleomonomers.
• In certain embodiments, the nucleic acid comprises two or more conformationally restricted nucleomonomers, wherein the two or more conformationally restricted nucleomonomers flank the one or more gaps of the second strand of the nucleic acid.
• In certain embodiments, the nucleic acid comprises two or more conformationally restricted nucleomonomers, wherein the two or more conformationally restricted nucleomonomers flank the one or more nicks of the second strand of the nucleic acid.
• In certain embodiments, the nucleic acid compound has a blunt end. In certain embodiments, the nucleic acid compound has a 3′-end overhang.
• In certain embodiments, the nucleic acid compound comprises a hydroxymethyl substituted nucleomonomer. In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In another aspect, the instant disclosure provides a use of a nucleic acid compound as described herein for the manufacture of a medicament for use in the therapy of disease.
• In another aspect, the instant disclosure provides a method for reducing the expression of a gene or reducing the function an endogenous nucleic acid based regulatory system of a cell, comprising administering a nucleic acid compound as described herein to a cell, wherein the nucleic acid compound reduces the expression of the gene in the cell.
• In another aspect, the instant disclosure provides a method for reducing the function of an endogenous nucleic acid based regulatory system of a cell, comprising administering a nucleic acid compound described herein to a cell, wherein the nucleic acid compound reduces the function of the endogenous nucleic acid based regulatory system in the cell.
• In certain embodiments, the cell is a human cell.
• In another aspect, the instant disclosure provides a method for treating or managing a disease or condition in a subject associated, linked, and/or resulting from aberrant nucleic acid expression, comprising administering to the subject in need of treatment or management a nucleic acid compound as disclosed herein, wherein the nucleic acid compound reduces the expression or function of the nucleic acid thereby treating or managing the disease or condition.
• In further embodiments, the nucleic acid compound is a single stranded nucleic acid comprising from 10 to 40 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40) nucleomonomers, wherein one or more of the from 10 to 40 nucleomonomers is a conformationally restricted nucleomonomer.
• In certain embodiments, the minimum percent occurrence of conformationally restricted nucleomonomers of the nucleic acid compound is greater than 0% and less than 95%, or greater than 0% and less than 85%, or greater than 0% and less than 75%, or greater than 10% and less than 70%, or greater than 20% and less than 60%, or greater than 30% and less than 55%, or greater than 40% and less than 60%.
• In certain embodiments, the percent of nucleomonomers of the from 10 to 40 nucleomonomers of nucleic acid compound that are conformationally restricted nucleomonomers is from 1% to 95%, or from 5% to 90%, or from 10% to 85%, or from 15% to 80%, or from 20% to 75%, or from 25% to 70%, or from 30% to 65%, or from 35% to 60%, or from 40% to 55%, or from 45% to 50%.
• In certain embodiments, every other nucleomonomer of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every third nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every forth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every fifth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every sixth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every seventh nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every eight nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every ninth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every tenth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OCH₃; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomer that are independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers that are independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In certain embodiments, the nucleic acid compound comprises one or more RNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises one or more DNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises RNA and DNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers.
• In certain embodiments, the nucleic acid compound has the following formula:
• 
  5′ A-B-A 3′
• wherein, A is independently, for each occurrence, a sequence of from 3 to 16 (or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) nucleomonomers, wherein the minimum percent occurrence of conformationally restricted nucleomonomers of the sequence is greater than 0% and less than 95%, or greater than 0% and less than 85%, or greater than 0% and less than 75%, or greater than 10% and less than 70%, or greater than 20% and less than 60%, or greater than 30% and less than 55%, or greater than 40% and less than 60%; and wherein B is independently, for each occurrence, is a sequence of from 4 to 8 (or 4, 5, 6, 7, or 8) nucleomonomers.
• In certain embodiments, the nucleic acid compound is from 10 to 40 nucleomonomers in length, from 12 to 30 nucleomonomers in length or from 12 to 14 nucleomonomers in length.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OCH₃; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers that are independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the one or more hydroxymethyl substituted nucleomonomers are independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In certain embodiments, B does not contain a conformationally restricted nucleomonomer.
• In certain embodiments, the nucleomonomers of B are DNA, phosphorothioates or a combination thereof.
• In certain embodiments, the nucleomonomers of A are RNA.
• In certain embodiments, the nucleic acid compound functions as an antisense RNA, microRNA or antagomir.
• In another embodiment, the nucleic acid compound is single stranded and has no double stranded region.
• In another aspect, the instant disclosure provides a nucleic acid compound comprising a first strand having from 10 to 60 (or 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) nucleomonomers, and a second strand complementary to the first strand, wherein the first strand and the second strand can anneal to form 8 to 60 base pairs, and wherein one or more of the nucleomonomers of the first strand or the second strand is a conformationally restricted nucleomonomer.
• In certain embodiments, the melting temperature of the nucleic acid compound is from 40° C. to 100° C., or from 60° C. to 90° C., or from 75° C. to 80° C.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or wherein from 40% to 50% of the nucleomonomers of the first strand or second strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, the first strand is from 10 to 40 nucleomonomers in length. In other embodiments, the first strand is from 15 to 35 nucleomonomers in length. In yet other embodiments, the first strand is from 18 to 30 nucleomonomers in length. In yet other embodiments, the first strand is from 19 to 23 nucleomonomers in length. In yet another embodiment, the first strand is from 25 to 30 nucleomonomers in length.
• In certain embodiments, the second strand is from 8 to 60 nucleomonomers in length. In other embodiments, the second strand is from 10 to 40 nucleomonomers in length. In yet other embodiments, the second strand is from 15 to 35 nucleomonomers in length. In yet other embodiments, the second strand is from 18 to 30 nucleomonomers in length. In yet other embodiments, the second strand is from 19 to 23 nucleomonomers in length. In yet another embodiment, the second strand is from 25 to 30 nucleomonomers in length.
• In certain embodiments, any one or more of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 counting from the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, any one or more of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 counting from the 3′-end of the first strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, any one or more of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 counting from the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, any one or more of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 counting from the 5′-end of the second strand is occupied by the same or different conformationally restricted nucleomonomer.
• In certain embodiments, the nucleic acid compound comprises RNA. In certain embodiments, the nucleic acid compound comprises DNA. In certain embodiments, the nucleic acid compound comprises RNA and DNA.
• In certain embodiments, the nucleic acid compound is an siRNA.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• where X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• where X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more Monomer R and one or more Monomer Q.
• In certain embodiments, the first and second strands are a contiguous strand of nucleomonomers. In certain embodiments, the second strand has one or more nicks. In certain embodiments, the second strand has one or more gaps. In a related embodiment, the one or more gaps, independently for each occurrence, comprise from 1 to 10 (or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) unpaired nucleomonomers.
• In certain embodiments, the nucleic acid compound has a blunt end. In certain embodiments, the nucleic acid compound has a 3′-end overhang.
• In certain embodiments, the nucleic acid compound comprises a hydroxymethyl substituted nucleomonomer. In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In one aspect, the disclosure provide for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 10 to 24 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24) base pairs, wherein any one or more of the last three positions at the 5′-end of the sense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer, and wherein any one or more of the last 10 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In one aspect, the disclosure provide for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 10 to 24 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24) base pairs, wherein any one or more of the last three positions at the 5′-end of the sense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer, and wherein any one or more of the last 10 positions at the 5′-end of the sense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the antisense strand is from 10 to 24 nucleomonomers in length.
• In another aspect, the senses strand is from 10 to 24 nucleomonomers in length.
• In another aspect, no more than two conformationally restricted nucleomonomers are adjacent to one another.
• In another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In yet another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the antisense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In another aspect, the nucleic acid compound further comprises that one or more of positions 5, 6, 7 and 8 of the antisense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer, wherein the positions of the antisense strand are numbered beginning with position 1 at the 5′ end of the antisense strand.
• In another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In yet another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the antisense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers that are independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the one or more hydroxymethyl substituted nucleomonomers are independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In another aspect, the nucleic acid compound has a double-stranded region of 10 to 23 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 12 to 21 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 14 to 21 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 15 to 21 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 16 to 21 base pairs.
• In another aspect, the nucleic acid compound has a blunt end.
• In another aspect, the nucleic acid compound further comprises a 3′-end overhang. In another aspect, the 3′-end overhang comprises nucleotides. In another aspect, the 3′-end overhang comprises non-nucleotide monomers. In another aspect, the 3′-end overhang comprise both nucleotides and non-nucleotide monomers.
• In another aspect, the 3′-end overhang is from 1 to 20 (or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18) nucleomonomers in length. In another aspect, the 3′-end overhang is from 3 to 18 (or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) nucleomonomers in length. In another aspect, the 3′-end overhang is from 5 to 16 (or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) nucleomonomers in length.
• In any aspect disclosed herein, the 3′-end overhang is an overhang of the sense strand. In any aspect disclosed herein, the 3′-end overhang is an overhang of the antisense strand. In any aspect disclosed herein, the sense strand has a 3′-overhang and the antisense strand has a 3′-end overhang, which may be the same or different. In another aspect, the 3′-end overhang is from 1 to 5 (or 1, 2, 3, 4 or 5) nucleomonomers in length.
• In another aspect, the 3′-end overhang is selected from the group of overhangs with a length of 1 nucleotide, 2 nucleotides, 3 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides and 8 nucleotides, and/or 1 hydroxymethyl substituted nucleomonomer, 2 hydroxymethyl substituted nucleomonomers, 3 hydroxymethyl substituted nucleomonomers, 4 hydroxymethyl substituted nucleomonomers, 5 hydroxymethyl substituted nucleomonomers, 6 hydroxymethyl substituted nucleomonomers, 7 hydroxymethyl substituted nucleomonomers and 8 hydroxymethyl substituted nucleomonomers, and combinations thereof.
• In one aspect, this disclosure provides for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) base pairs, wherein the last position of the 3′-end of the antisense strand and the last position of the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer, and wherein any one or more of the last 15 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In one aspect, this disclosure provides for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) base pairs, wherein the last position of the 3′-end of the antisense strand and the last position of the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer, and wherein any one or more of the last 15 positions at the 5′-end of the sense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the antisense strand is from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) nucleomonomers in length.
• In another aspect, the senses strand is from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) nucleomonomers in length.
• In some embodiments, no more than two conformationally restricted nucleomonomers are adjacent to one another.
• In another aspect, the last two positions of the 3′-end of the antisense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers that are independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the one or more hydroxymethyl substituted nucleomonomers are independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In another aspect, the nucleic acid compound has a double-stranded region of 25 to 40 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 25 to 35 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 25 to 30 base pairs. In another aspect, the nucleic acid compound has a double-stranded region of 25 to 27 base pairs.
• In another aspect, the nucleic acid compound has a blunt end.
• In another aspect, the nucleic acid compound further comprises a 3′-end overhang. In another aspect, the 3′-end overhang comprises nucleotides. In another aspect, the 3′-end overhang comprises non-nucleotide monomers. In another aspect, the 3′-end overhang comprise both nucleotides and non-nucleotide monomers.
• In another aspect, the 3′-end overhang is from 1 to 20 (or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18) nucleomonomers in length. In another aspect, the 3′-end overhang is from 3 to 18 (or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) nucleomonomers in length.
• In another aspect, the 3′-end overhang is from 5 to 16 (or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 16) nucleomonomers in length. In any aspect disclosed herein, the 3′-end overhang is an overhang of the sense strand. In any aspect disclosed herein, the 3′-end overhang is an overhang of the antisense strand. In any aspect disclosed herein, the sense strand has a 3′-overhang and the antisense strand has a 3′-end overhang, which may be the same or different. In another aspect, the 3′-end overhang is from 1 to 5 (or 1, 2, 3, 4 or 5) nucleomonomers in length.
• In another aspect, the 3′-end overhang is selected from the group of overhangs with a length of 1 nucleotide, 2 nucleotides, 3 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides and 8 nucleotides, and/or 1 hydroxymethyl substituted nucleomonomer, 2 hydroxymethyl substituted nucleomonomers, 3 hydroxymethyl substituted nucleomonomers, 4 hydroxymethyl substituted nucleomonomers, 5 hydroxymethyl substituted nucleomonomers, 6 hydroxymethyl substituted nucleomonomers, 7 hydroxymethyl substituted nucleomonomers and 8 hydroxymethyl substituted nucleomonomers, and combinations thereof.
• In one aspect, this disclosure provide for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) base pairs, wherein one or more of positions 21, 22 and 23 of the sense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer, wherein the positions of the sense strand are numbered beginning with position 1 at the 5′-end of the sense strand, and wherein any one or more of the last 15 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In one aspect, this disclosure provide for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) base pairs, wherein one or more of positions 21, 22 and 23 of the sense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer, wherein the positions of the sense strand are numbered beginning with position 1 at the 5′-end of the sense strand, and wherein any one or more of the last 15 positions at the 5′-end of the sense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In one aspect, this disclosure provide for a nucleic acid compound comprising a sense strand and an antisense strand, and a double-stranded region having from 25 to 60 (or 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60) base pairs, wherein one or more of positions 18, 19, 20, 21, and 22 of the antisense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer, wherein the positions of the sense strand are numbered beginning with position 1 at the 3′-end of the antisense strand, and wherein any one or more of the last 15 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the antisense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In another aspect, the nucleic acid compound further comprises that one or both of the last two positions of the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer.
• In another aspect, the hydroxymethyl substituted nucleomonomer is a 2′-3′-seco-nucleomonomer.
• In another aspect, the hydroxymethyl substituted nucleomonomer is selected from:
• 
• wherein R is selected from the group consisting of a hydrogen, an alkyl group, a cholesterol derivative, a fluorophore, a polyamine, a fatty acid, an amino acid, a saccharide, and a polypeptide, wherein Base is any purine, pyrimidine, or derivative or analogue thereof.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments, the one or more hydroxymethyl substituted nucleomonomer are independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the one or more hydroxymethyl substituted nucleomonomers are independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In another aspect, the nucleic acid compound further comprises a nucleotide analogue selected from the group consisting of 2′-O-alkyl-RNA monomers, 2′-amino-DNA monomers, 2′-fluoro-DNA monomers, LNA monomers, PNA monomers, HNA monomers, ANA monomers, FANA monomers, CeNA monomers, ENA monomers, DNA monomers, and INA monomers.
• In another aspect, the instant disclosure provides for the use of a nucleic acid compound as disclosed herein for the manufacture of a medicament for use in the therapy of cancer.
• In a related aspect, one or more hydroxymethyl substituted nucleomonomer(s) are at one or more of positions 5, 6, 7 or 8 counting from the 5′-end of the antisense strand.
• In a related aspect, one or more hydroxymethyl substituted nucleomonomer(s) are at position 7 counting from the 5′-end of the antisense strand.
• In a related aspect, the double-stranded region has 19 or 20 base pairs.
• In a related aspect, the sense strand and the antisense strand each have 21 or 22 nucleomonomers.
• In a related aspect, the dsRNA has a 3′-end overhang.
• In a related aspect, the dsRNA has a blunt end.
• In another aspect, the disclosure provides a nucleic acid compound (e.g., dsRNA) that downregulates the expression of a gene, the nucleic acid compound comprising a sense strand and an antisense strand, a double-stranded region having from 25 to 60 base pairs, and wherein the last two nucleomonomers of the 3′-end of the antisense strand and the last nucleomonomer of the 3′-end of the sense strand are hydroxymethyl substituted nucleomonomers, and wherein any one or more of the last 15 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the disclosure provides a nucleic acid compound (e.g., dsRNA) that downregulates the expression of a gene, the nucleic acid compound comprising a sense strand and an antisense strand, a double-stranded region having from 25 to 60 base pairs, and wherein the last two nucleomonomers of the 3′-end of the antisense strand and the last nucleomonomer of the 3′-end of the sense strand are hydroxymethyl substituted nucleomonomers, and wherein any one or more of the last 15 positions at the 5′-end of the sense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the disclosure provides a nucleic acid compound (e.g., dsRNA) that downregulates the expression of a gene, the nucleic acid compound comprising a sense strand and an antisense strand, a double-stranded region having from 25 to 60 base pairs, and wherein one or more hydroxymethyl substituted nucleomonomer(s) are at one or more of positions of the sense strand that inhibit processing of the dsRNA by a Dicer enzyme, and wherein any one or more of the last 15 positions at the 3′-end of the antisense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In another aspect, the disclosure provides a nucleic acid compound (e.g., dsRNA) that downregulates the expression of a gene, the nucleic acid compound comprising a sense strand and an antisense strand, a double-stranded region having from 25 to 60 base pairs, and wherein one or more hydroxymethyl substituted nucleomonomer(s) are at one or more of positions of the sense strand that inhibit processing of the dsRNA by a Dicer enzyme, and wherein any one or more of the last 15 positions at the 5′-end of the sense strand is occupied by the same or different conformationally restricted nucleomonomer.
• In a related aspect, one or more hydroxymethyl substituted nucleomonomer(s) are at one or more of positions 21, 22 or 23 of the sense strand counting from the 5′-end of the sense strand.
• In a related aspect, one or more hydroxymethyl substituted nucleomonomer(s) are at one or more of positions 18, 19, 20, 21 or 22 of the antisense strand counting from the 3′-end of the antisense strand.
• In one aspect, the instant disclosure provides for a nucleic acid compound comprising at least three strands, designated herein as A, S1 and S2 (A:S1S2), wherein the Si strand and the S2 strand are complementary to, and form base pairs (bp) with, non-overlapping regions of the A strand. Thus, for the nucleic acid compounds described herein; the double-stranded region (or a duplex) formed by the annealing of the Si strand and the A strand is distinct from the double-stranded region formed by the annealing of the S2 strand and the A strand. An A:S1 duplex may be separated from an A:S2 duplex by a “gap” resulting from at least one unpaired nucleomonomer in the A strand that is positioned between the A:S1 duplex and the A:S2 duplex and that is distinct from any one or more unpaired nucleomonomer at the 3′ end of either or both of the A, S1, and/or S2 strand. Alternatively, an A:S1 duplex may be separated from an A:S2 duplex by a “nick” (lack of a phosphodiester bond between adjacent nucleomonomers) such that there are no unpaired nucleotides in the A strand that are positioned between the A:S1 duplex and the A:S2 duplex such that the only unpaired nucleotide, if any, is at the 3′ end of either or both of the A, S1, and/or S2 strand.
• In one aspect, the nucleic acid compound comprises a first strand that is complementary to a target nucleic acid (e.g., mRNA or other nucleic acid molecule), and a second strand and a third strand that are each complementary to non-overlapping regions of the first strand, wherein the second strand and third strands can anneal with the first strand to form at least two double-stranded regions separated by a gap of from 1 to 10 (or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) nucleomonomers or nick, wherein the total number of base pairs of the double-stranded is from about 10 base pairs to about 60 base pairs, and wherein one or more of the nucleomonomers is a conformationally restricted nucleomonomer.
• In certain embodiments, the minimum percent occurrence of conformationally restricted nucleomonomers of the nucleic acid compound is greater than 0% and less than 95%, or greater than 0% and less than 85%, or greater than 0% and less than 75%, or greater than 10% and less than 70%, or greater than 20% and less than 60%, or greater than 30% and less than 55%, or greater than 40% and less than 60%.
• In certain embodiments, the percent of nucleomonomers that are conformationally restricted nucleomonomers is from 1% to 95%, or from 5% to 90% (or 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%), or from 10% to 85% (or 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85%), or from 15% to 80%, or from 20% to 75%, or from 25% to 70%, or from 30% to 65%, or from 35% to 60%, or from 40% to 55%, or from 45% to 50%.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or wherein from 40% to 50% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the second strand of the nucleic acid compound are conformationally restricted nucleomonomers, or wherein from 40% to 50% of the nucleomonomers of the second strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the second strand or the third strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the second strand or the third strand of the nucleic acid compound are conformationally restricted nucleomonomers, or wherein from 40% to 50% of the nucleomonomers of the second strand or the third strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, every other nucleomonomer of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every third nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every forth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every fifth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every sixth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every seventh nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every eight nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every ninth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, every tenth nucleomonomer counting from the 5′-end of the nucleic acid compound is a conformationally locked nucleomonomer.
• In certain embodiments, each double-stranded region comprises an equal number of the same or different conformationally restricted nucleomonomers.
• In certain embodiments, each double-stranded region comprises one or more conformationally restricted nucleomonomers, wherein the one or more conformationally restricted nucleomonomers may be the same or different.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more of the same or different Monomer R and one or more of the same or different Monomer Q.
• In certain embodiments the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In certain embodiments, the nucleic acid compound comprises one or more RNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises one or more DNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises RNA and DNA nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomers.
• In certain embodiments, at least one double-stranded region is from about 5 base pairs up to 13 base pairs.
• In certain embodiments, the double-stranded regions combined total from about 15 base pairs to about 40 base pairs.
• In certain embodiments, the first strand is from about 10 to about 40 nucleomonomers in length, and the second and third strands are each, individually, from about 5 to about 20 nucleomonomers, wherein the combined length of the second and third strands is about 10 nucleomonomers to about 40 nucleomonomers.
• In other embodiments, the nucleic acid compound is a RISC activator (e.g., the first strand has about 15 nucleotides to about 25 nucleotides) or a Dicer substrate (e.g., the first strand has about 26 nucleotides to about 40 nucleotides).
• In some embodiments, the gap comprises at least one to ten unpaired nucleomonomers in the first strand positioned between the double-stranded regions formed by the second and third strands when annealed to the first strand.
• In some embodiments, the double-stranded regions are separated by a nick.
• In certain embodiments, the nick or gap is located 10 nucleomonomers from the 5′-end of the first (antisense) strand or at the Argonaute cleavage site.
• In another embodiment, the nick or gap is positioned such that the thermal stability is maximized for the first and second strand duplex and for the first and third strand duplex as compared to the thermal stability of such meroduplexes having a nick or gap in a different position.
• In one aspect of the disclosure, the number of hydroxymethyl substituted nucleomonomers in the antisense strand is 10. In other embodiments of the disclosure, the number of hydroxymethyl substituted nucleomonomer(s) in the antisense strand is 9, 8, 7, 6, 5, 4, 3, 2 or 1, respectively.
• In another aspect, all nucleomonomers of the antisense strand are hydroxymethyl substituted nucleomonomers.
• In one aspect of the disclosure, all hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions 1, 2, 3, 4, 5, 6, 7, and/or 8, wherein the positions are counted from the 5′ end of the antisense strand. Even more preferably, the hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions 2, 3, 4, 5, 6, and/or 7, counted from the 5′ end of the antisense strand or in the corresponding to the so-called seed region of a microRNA. In another aspect, the hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions 4, 5, 6, 7 and/or 8, counted from the 5′ end of the antisense strand. In another aspect, the hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions 6, 7 and/or 8, counted from the 5′ end of the antisense strand. In another aspect, the hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions in the antisense strand that reduce the microRNA activity of the nucleic acid compound compared to the same nucleic acid compound without hydroxymethyl substituted nucleomonomers. Thus, presence of hydroxymethyl substituted nucleomonomers in the aforementioned regions may prevent the antisense strand from acting as a microRNA, which reduces off target effects when the antisense strand is intended to function as siRNA.
• In a preferred embodiment, at least one hydroxymethyl substituted nucleomonomer is present in any one of positions 9, 10, 11, 12, 13, 14, 15, and/or 16, wherein the positions are counted from the 5′-end of the antisense strand. Even more preferred is hydroxymethyl substituted nucleomonomers present in any one of positions 9, 10, 11, 12, 13, 14, 15, and/or 16, wherein the positions are counted from the 5′ end of the antisense strand. In another embodiment, hydroxymethyl substituted nucleomonomers in the antisense strand is present in all of positions 9, 10, 11, 12, 13, 14, 15, and/or 16. In one embodiment, hydroxymethyl substituted nucleomonomer are only present in regions 9, 10, 11, 12, 13, 14, 15, and/or 16 and not in the rest of the antisense strand.
• Even more preferably, the hydroxymethyl substituted nucleomonomers in the antisense strand is present in position 9, 10, and/or 11, counted from the 5′ end of the antisense strand, and preferably, not in the rest of the oligonucleotide. In another aspect, the hydroxymethyl substituted nucleomonomers in the antisense strand are present in positions in the antisense strand that enhance the microRNA activity of the nucleic acid compound compared to the same nucleic acid compound without hydroxymethyl substituted nucleomonomers. The presence of hydroxymethyl substituted nucleomonomers in the aforementioned regions may induce the antisense strand to act as a microRNA, i.e. ensure that the siRNA effect will be minimal and the microRNA effect much higher.
• In another embodiment of the disclosure, the number of hydroxymethyl substituted nucleomonomers in the passenger strand of a nucleic acid compound of the disclosure is 10. In other embodiments of the disclosure, the number of hydroxymethyl substituted nucleomonomers in the passenger strand of a nucleic acid compound of the disclosure is 9, 8, 7, 6, 5, 4, 3, 2 or 1, respectively.
• In another embodiment, all nucleomonomers of the passenger strand of a nucleic acid compound of the disclosure are hydroxymethyl substituted nucleomonomers.
• In certain aspects, the sense (passenger strand) of a nucleic acid compound comprises one or more hydroxymethyl substituted nucleomonomer(s). In certain aspects, the sense (passenger strand) of a nucleic acid compound comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 hydroxymethyl substituted nucleomonomer(s). In certain aspects, the entire sense (passenger strand) of a nucleic acid compound comprises hydroxymethyl substituted nucleomonomer(s).
• In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 1, 2, 3, 4, 5, 6, 7, and/or 8 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 1, 2, 3, and/or 4 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 1, 2 and/or 3 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 5, 6, 7, and/or 8 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 7 and/or 8 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, hydroxymethyl substituted nucleomonomers in the sense strand are present in positions in the sense strand of an nucleic acid compound that reduce the RNAi activity of the sense strand of the nucleic acid compound compared to the same nucleic acid compound without hydroxymethyl substituted nucleomonomers.
• In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 9, 10, 11, 12, 13, 14, 15, and/or 16 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 9, 10, and/or 11, wherein the positions are counted from the 5′-end of the sense strand.
• In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and/or 32 wherein the positions are counted from the 5′-end of the sense strand. In certain aspects, a hydroxymethyl substituted nucleomonomer in the sense strand is present in positions 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10, wherein the positions are counted from the 3′-end of the sense strand.
• In one embodiment, both the antisense strand and the passenger strand of a nucleic acid compound of the disclosure contain one or more hydroxymethyl substituted nucleomonomer(s).
• In certain embodiments, one or both of the last two positions at the 3′-end of the sense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer. In certain embodiments, one or both of the last two positions at the 3′-end of the antisense strand are occupied by the same or different hydroxymethyl substituted nucleomonomer. In certain embodiments, any one or more of the last three positions at the 5′-end of the sense strand is occupied by the same or different hydroxymethyl substituted nucleomonomer. In certain embodiments, at least one hydroxymethyl substituted nucleomonomer is in a double-stranded region of the nucleic acid compound.
• In yet another embodiment, the core double stranded region of a nucleic acid compound of the disclosure is shorter than 10 base pairs and thus comprises from one to nine base pairs.
• In one aspect, the present disclosure provides a nucleic acid compound capable of mediating nucleic acid modifications of a target nucleic acid. Such nucleic acid compound may, for example, be an siRNA, microRNA or microRNA precursor (pre-microRNA).
• In any of the aspects of this disclosure, some embodiments provide a nucleic acid comprising one or more 5-methyluridine (ribothymidine), a 2-thioribothymidine, or 2′-β-methyl-5-methyluridine, deoxyuridine, locked nucleic acid (LNA) molecule, or a universal-binding nucleotide, or a G clamp. Exemplary universal-binding nucleotides include C-phenyl, C-naphthyl, inosine, azole carboxamide, 1-β-D-ribofuranosyl-4-nitroindole, 1-β-D-ribofuranosyl-5-nitroindole, 1-β-D-ribofuranosyl-6-nitroindole, or 1-β-D-ribofuranosyl-3-nitropyrrole. In some embodiments, the nucleic acid further comprises a 2′-sugar substitution, such as a 2′-O-methyl, 2′-O-methoxyethyl, 2′-O-2-methoxyethyl, 2′-O-allyl, or halogen (e.g., 2′-fluoro).
• In certain embodiments, the nucleic acid further comprises a terminal cap substituent on one or both ends of one or more of the first strand, second strand, or third strand, such as independently an alkyl, abasic, deoxy abasic, glyceryl, dinucleotide, acyclic nucleotide, or inverted deoxynucleotide moiety. In other embodiments, the nucleic acid further comprises at least one modified internucleoside linkage, such as independently a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl phosphonate, alkyl phosphonate, 3′-alkylene phosphonate, 5′-alkylene phosphonate, chiral phosphonate, phosphonoacetate, thiophosphonoacetate, phosphinate, phosphoramidate, 3′-amino phosphoramidate, aminoalkylphosphoramidate, thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate, or boranophosphate linkage.
• In any of the aspects disclosed herein, the nucleic acid compound comprises a 2′-β-methyl nucleomonomer. In a related aspect, the nucleic acid compound comprises from zero to twelve 2′-O-methyl nucleomonomer(s) (or 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 2′-O-methyl nucleomonomer(s)). In a related aspect, the passenger strand of the nucleic acid compound comprises from zero to twelve 2′-O-methyl nucleomonomer(s) (or 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 2′-O-methyl nucleomonomer(s)). In a related aspect, the guide strand of the nucleic acid compound comprises from zero to six 2′-O-methyl nucleomonomer(s) (or 0, 1, 2, 3, 4, 5 or 6 2′-O-methyl nucleomonomer(s)). In certain aspects, the hydroxymethyl substituted monomer is a 2′-O-methyl nucleomonomer.
• In any of the aspects of this disclosure, some embodiments provide nucleic acid compound comprising an overhang of one to five (or 1, 2, 3, 4, 5) nucleomonomers on at least one 3′-end that is not part of the gap. In any of the aspects of this disclosure, some embodiments provide a nucleic acid compound has a blunt end at one or both ends. In other embodiments, the 5′-terminal of the sense strand, antisense strand or both strands is a hydroxyl or a phosphate.
• In one embodiment, the nucleic acid compound may be a bifunctional nucleic acid compound having two blunt-ends and a hydroxymethyl substituted nucleomonomer at position(s) 5, 6, 7, and/or 8 from the 5′-end of each of the guide strand and passenger strand, and wherein nucleic acid compound comprises one or more conformationally restricted nucleomonomers.
• In one embodiment, the bifunctional nucleic acid compound comprise two blunt-ends, a sense strand and a antisense strand, wherein the sense strand comprises an hydroxymethyl substituted nucleomonomer at position(s) 5, 6, 7, and/or 8 from the 5′-end of the sense strand, and the antisense strand comprises an hydroxymethyl substituted nucleomonomer at position(s) 5, 6, 7, and/or 8 from the 5′-end of antisense strand, and wherein the sense strand is complementary to a first region of a target nucleic acid and the antisense region is complementary to a second region of the target nucleic acid, wherein the first region and the second region are non-overlapping regions of the target nucleic acid. In a related embodiment, the first and second regions of the target nucleic acid partially overlap.
• In one embodiment, the bifunctional nucleic acid compound comprise two blunt-ends, a sense strand and a antisense strand, wherein the sense strand comprises an hydroxymethyl substituted nucleomonomer at position(s) 5, 6, 7, and/or 8 from the 5′-end of the sense strand, and the antisense strand comprises an hydroxymethyl substituted nucleomonomer at position(s) 5, 6, 7, and/or 8 from the 5′-end of antisense strand, and wherein the sense strand is complementary to a first region of a first target nucleic acid and the antisense region is complementary to a second region of a second target nucleic acid, wherein the first target nucleic acid and the second target nucleic acid are different target nucleic acid molecules, or have less than 95% homology, or 90% homology, or 85% homology, or 80% homology, or 75% homology, or 70% homology, or 65% homology, or 60% homology, or 55% homology or 50% homology. In a related embodiment, the first and second target nucleic acid molecules are in the same cellular pathway.
• In one aspect, the present disclosure provides a nucleic acid compound comprising a first strand and a second strand complementary to the first strand, wherein the first strand and the second strand can anneal to form a double-stranded region, and wherein the double-stranded region comprises one or more mismatches, and wherein one or more of the nucleomonomers of the first strand or the second strand is a conformationally restricted nucleomonomer
• In certain embodiments, the first strand has from 10 to 60 (or 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) nucleomonomers.
• In certain embodiments, the double-stranded region comprises from 8 to 60 (or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60) base pairs.
• In certain embodiments, the double-stranded region comprises two mismatches. In certain embodiments, the double-stranded region comprises three mismatches. In certain embodiments, the double-stranded region comprises four mismatches. In certain embodiments, the double-stranded region comprises five mismatches. In certain embodiments, the double-stranded region comprises six mismatches. In certain embodiments, the double-stranded region comprises seven mismatches. In certain embodiments, the double-stranded region comprises eight mismatches.
• In certain embodiments, the first and second strands are joined by a non-pairing region of nucleomonomers.
• In certain embodiments, the nucleic compound comprises a short hairpin structure.
• In certain embodiments, the nucleic compound is a short hairpin RNA (shRNA).
• In certain embodiments, the conformationally restricted nucleomonomer reduces or eliminates the microRNA activity of the nucleic acid compound.
• In one aspect, the instant disclosure provides a nucleic acid compound comprising a strand having from 10 to 100 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100) nucleomonomers, two or more double-strand regions, wherein the double-stranded regions are separated by mismatches, wherein the nucleic acid compound comprises a hairpin turn, and wherein one or more of the nucleomonomers is a conformationally restricted nucleomonomer.
• In one aspect, the instant disclosure provides a nucleic acid compound comprising a strand having from 10 to 100 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100) nucleomonomers, a double-strand region, a hairpin turn, and wherein one or more of the nucleomonomers is a conformationally restricted nucleomonomer.
• In certain embodiments, the double-stranded region comprises one mismatch. In certain embodiments, the double-stranded region comprises two mismatches. In certain embodiments, the double-stranded region comprises three mismatches. In certain embodiments, the double-stranded region comprises four mismatches. In certain embodiments, the double-stranded region comprises five mismatches. In certain embodiments, the double-stranded region comprises six mismatches. In certain embodiments, the double-stranded region comprises seven mismatches. In certain embodiments, the double-stranded region comprises eight mismatches.
• In certain embodiments, the conformationally restricted nucleomonomer reduces or eliminates the microRNA activity of the nucleic acid compound.
• In certain embodiments, the conformationally restricted nucleomonomer is located in the seed region of the nucleic acid compound.
• In certain embodiments, the melting temperature of the nucleic acid compound is from 40° C. to 100° C., or from 60° C. to 90° C., or from 75° C. to 80° C.
• In certain embodiments, from 1% to 75% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 20% to 60% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers, or from 40% to 50% of the nucleomonomers of the first strand of the nucleic acid compound are conformationally restricted nucleomonomers.
• In certain embodiments, the nucleic acid compound comprises RNA. In certain embodiments, the nucleic acid compound comprises DNA. In certain embodiments, the nucleic acid compound comprises RNA and DNA.
• In other embodiments, the first strand is from 10 to 40 (or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40) nucleomonomers in length. In other embodiments, the first strand is from 10 to 30 nucleomonomers in length.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer R and has the following formula:
• 
• where X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂; R₂and R₃are independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, S—F, CN, N₃, OCH₃, monosphosphate, diphosphate, triphosphate, monophosphate, diphosphonate, triphosphonate, an amino acid ester with an OH group the sugar portion, or a prodrug of the monophosphate, diphosphate, triphosphate, monophosphonate, diphosphonate, or triphosphonate, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is independently for each occurrence a nucleobase or nucleobase analog.
• In certain embodiments, the conformationally restricted nucleomonomer is Monomer Q and has the following formula:
• 
• where X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂; Z is independently for each occurrence selected from N or CH; R₂is independently for each occurrence selected from hydrogen, F, OH, or OMe; R₁and R₃are independently for each occurrence selected from hydrogen, OH, P(OR)₂, P(O)(OR)₂, P(S)(OR)₂, P(O)(SR)OR, acyl, carbobenzoxy, trifluoroacetyl, p-nitrophenyloxycarbonyl, or any suitable protecting group or an activating group for building oligomers; and R is independently for each occurrence selected from H, 2-cyanoethyl, diisopropylamino, alkyl, alkenyl, alkynyl, or a hydrophobic masking group, where R can be same or different from each other in case of (OR)₂, or (SR)OR.
• In certain embodiments, the nucleic acid compound comprises one or more Monomer R and one or more Monomer Q.
• In certain embodiments, the nucleic acid compound further comprises a second strand.
• In certain embodiments, the second strand comprises one or more conformationally restricted nucleomonomers.
• In certain embodiments, the nucleic acid compound further comprises a hydroxymethyl substituted nucleomonomer. In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer A, Monomer C, Monomer E, Monomer G, Monomer I, Monomer K, Monomer M, and Monomer O; wherein, X is independently for each occurrence selected from O, S, or —CH₂; Z is independently for each occurrence selected from hydrogen, OH, CH₂OH, CH₃or saturated or unsaturated C(2-22) alkyl chain; J is independently for each occurrence selected from P or S; R₂is independently for each occurrence selected from hydrogen, OH, O-alkyl, F, SH, S-alkyl, SF, NH(CH═O), NH(C═O)—C(1-22) saturated or unsaturated alkyl chain, cycloalkyl, aryl or heterocyclic; and B is a nucleobase or nucleobase analog.
• In certain embodiments, the hydroxymethyl substituted nucleomonomer is independently for each occurrence selected from Monomer B, Monomer D, Monomer F, Monomer H, Monomer J, Monomer L, Monomer N and Monomer P; wherein, B is a nucleobase or nucleobase analog.
• In certain embodiments, the first strand is from 10 to 40 nucleomonomers in length or from 10 to 30 nucleomonomers in length
Synthesis of Nucleic Acid Molecules
• Exemplary molecules of the instant disclosure are recombinantly produced, chemically synthesized, or a combination thereof. Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers et al.,Methods in Enzymol.211:3-19, 1992; Thompson et al., PCT Publication No. WO 99/54459, Wincott et al.,Nucleic Acids Res.23:2677-2684, 1995; Wincott et al.,Methods Mol. Bio.74:59, 1997; Brennan et al.,Biotechnol Bioeng.61:33-45, 1998; and Brennan, U.S. Pat. No. 6,001,311. Synthesis of RNA, including certain dsRNA molecules and analogs thereof of this disclosure, can be made using the procedure as described in Usman et al.,J. Am. Chem. Soc.109:7845, 1987; Scaringe et al.,Nucleic Acids Res.18:5433, 1990; and Wincott et al.,Nucleic Acids Res.23:2677-2684, 1995; Wincott et al.,Methods Mol. Bio.74:59, 1997.
• In certain embodiments, the nucleic acid molecules of the present disclosure can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al.,Science256:9923, 1992; Draper et al., PCT Publication No. WO 93/23569; Shabarova et al.,Nucleic Acids Res.19:4247, 1991; Bellon et al.,Nucleosides&Nucleotides16:951, 1997; Bellon et al.,Bioconjugate Chem.8:204, 1997), or by hybridization following synthesis or deprotection.
• In certain embodiments, double-stranded portions of dsRNAs, in which two or more strands pair up, are not limited to completely paired nucleotide segments, and may contain non-pairing portions due to a mismatch (the corresponding nucleotides are not complementary), bulge (lacking in the corresponding complementary nucleotide on one strand), overhang, or the like. Non-pairing portions can be contained to the extent that they do not interfere with dsRNA formation and function. In certain embodiments, a “bulge” may comprise 1 to 2 non-pairing nucleotides, and the double-stranded region of dsRNAs in which two strands pair up may contain from about 1 to 7, or about 1 to 5 bulges. In addition, “mismatch” portions contained in the double-stranded region of dsRNAs may include from about 1 to 7, or about 1 to 5 mismatches. In other embodiments, the double-stranded region of dsRNAs of this disclosure may contain both bulge and mismatched portions in the approximate numerical ranges specified herein.
• A dsRNA or analog thereof of this disclosure may be further comprised of a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the dsRNA to the antisense region of the dsRNA. In one embodiment, a nucleotide linker can be a linker of more than about 2 nucleotides length up to about 10 nucleotides in length. In another embodiment, the nucleotide linker can be a nucleic acid aptamer.
• A non-nucleotide linker may be comprised of an abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g., polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser,Nucleic Acids Res.18:6353, 1990, andNucleic Acids Res.15:3113, 1987; Cload and Schepartz,J. Am. Chem. Soc.113:6324, 1991; Richardson and Schepartz,J. Am. Chem. Soc.113:5109, 1991; Ma et al.,Nucleic Acids Res.21:2585, 1993, andBiochemistry32:1751, 1993; Durand et al.,Nucleic Acids Res.18:6353, 1990; McCurdy et al.,Nucleosides&Nucleotides10:287, 1991; Jaschke et al.,Tetrahedron Lett.34:301, 1993; Ono et al.,Biochemistry30:9914, 1991; Arnold et al., PCT Publication No. WO 89/02439; Usman et al., PCT Publication No. WO 95/06731; Dudycz et al., PCT Publication No. WO 95/11910 and Ferentz and Verdine,J. Am. Chem. Soc.113:4000, 1991. The synthesis of a dsRNA molecule of this disclosure, which can be further modified, comprises: (a) synthesis of a first (antisense) strand and synthesis of a second (sense) strand and a third (sense) strand that are each complementary to non-overlapping regions of the first strand; and (b) annealing the first, second and third strands together under conditions suitable to obtain a dsRNA molecule. In another embodiment, synthesis of the first, second and third strands of a dsRNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the first, second, and third strands of a dsRNA molecule is by solid phase tandem oligonucleotide synthesis.
• Chemically synthesizing nucleic acid molecules with substitutions or modifications (base, sugar, phosphate, or any combination thereof) can prevent their degradation by serum ribonucleases, which may lead to increased potency. See, e.g., Eckstein et al., PCT Publication No. WO 92/07065; Perrault et al.,Nature344:565, 1990; Pieken et al.,Science253:314, 1991; Usman and Cedergren,Trends in Biochem. Sci.17:334, 1992; Usman et al.,Nucleic Acids Symp. Ser.31:163, 1994; Beigelman et al.,J. Biol. Chem.270:25702, 1995; Burgin et al.,Biochemistry35:14090, 1996; Burlina et al.,Bioorg. Med. Chem.5:1999, 1997; Thompson et al., Karpeisky et al.,Tetrahedron Lett.39:1131, 1998; Earnshaw and Gait,Biopolymers(Nucleic Acid Sciences) 48:39-55, 1998; Verma and Eckstein,Annu. Rev. Biochem.67:99-134, 1998; Herdewijn,Antisense Nucleic Acid Drug Dev.10:297, 2000; Kurreck,Eur. J. Biochem.270:1628, 2003; Dorsett and Tuschl,Nature Rev. Drug Discov.3:318, 2004; PCT Publication Nos. WO 91/03162; WO 93/15187; WO 97/26270; WO 98/13526; U.S. Pat. Nos. 5,334,711; 5,627,053; 5,716,824; 5,767, 264; 6,300,074. Each of the above references discloses various substitutions and chemical modifications to the base, phosphate, or sugar moieties of nucleic acid molecules, which can be used in the dsRNAs described herein. For example, oligonucleotides can be modified at the sugar moiety to enhance stability or prolong biological activity by increasing nuclease resistance. Representative sugar modifications include 2′-amino, 2′-C-allyl, 2′-fluoro, 2′-O-methyl, 2′-O-allyl, or 2′-H. Other modifications to enhance stability or prolong biological activity can be internucleoside linkages, such as phosphorothioate, or base-modifications, such as locked nucleic acids (see, e.g., U.S. Pat. Nos. 6,670,461; 6,794,499; 6,268,490), or 5-methyluridine or 2′-O-methyl-5-methyluridine in place of uridine (see, e.g., U.S. Patent Application Publication No. 2006/0142230). Hence, dsRNA molecules of the instant disclosure can be modified to increase nuclease resistance or duplex stability while substantially retaining or having enhanced RNAi activity as compared to unmodified dsRNA.
• In one embodiment, this disclosure features substituted or modified dsRNA molecules, such as phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, or alkylsilyl substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann,Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417, 1995; and Mesmaeker et al.,ACS,24-39, 1994.
• In another embodiment, a conjugate molecule can be optionally attached to a dsRNA or analog thereof that decreases expression of a target gene by RNAi. For example, such conjugate molecules may be polyethylene glycol, human serum albumin, polyarginine, Gln-Asn polymer, or a ligand for a cellular receptor that can, for example, mediate cellular uptake (e.g., HIV TAT, see Vocero-Akbani et al.,Nature Med.5:23, 1999; see also U.S. Patent Application Publication No. 2004/0132161). Examples of specific conjugate molecules contemplated by the instant disclosure that can be attached to a dsRNA or analog thereof of this disclosure are described in Vargeese et al., U.S. Patent Application Publication No. 2003/0130186, and U.S. Patent Application Publication No. 2004/0110296.
• In another embodiment, a conjugate molecule is covalently attached to a nucleic acid compound (e.g., dsRNA) or analog thereof that decreases expression of a target gene by RNAi via a biodegradable linker. In certain embodiments, a conjugate molecule can be attached at the 3′-end of either the sense strand, the antisense strand, or both strands of a dsRNA molecule provided herein. In another embodiment, a conjugate molecule can be attached at the 5′-end of either the sense strand, the antisense strand, or both strands of the dsRNA or analog thereof. In yet another embodiment, a conjugate molecule is attached at both the 3′-end and 5′-end of either the sense strand, the antisense strand, or both strands of a dsRNA molecule, or any combination thereof. In further embodiments, a conjugate molecule of this disclosure comprises a molecule that facilitates delivery of a dsRNA or analog thereof into a biological system, such as a cell. A person of skill in the art can screen dsRNA of this disclosure having various conjugates to determine whether the dsRNA-conjugate possesses improved properties (e.g., pharmacokinetic profiles, bioavailability, stability) while maintaining the ability to mediate RNAi in, for example, an animal model as described herein or generally known in the art.
• In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated.
• As used herein, “about” or “consisting essentially of” mean±20% of the indicated range, value, or structure, unless otherwise indicated.
• As used herein, the terms “include” and “comprise” are open ended and are used synonymously.
• It should be understood that the terms “a” and “an” as used herein refer to “one or more” of the enumerated components.
• The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives.
• As used herein, the term “linked” encompasses a covalent linkage either directly between two chemical entities (e.g., RNA and a hydroxymethyl substituted nucleomonomer), or indirectly between two chemical entities, for example via a linker.
• As used herein, the term “overhang” (e.g., 3′-end overhang or 3′ overhang) means an unpaired region of a nucleic acid compound which may contain all nucleotides, non-nucleotides (e.g., hydroxymethyl substituted nucleomonomers), or a combination of nucleotides and non-nucleotides.
• As used herein, the term “nucleobase analog” refers to a substituted or unsubstituted nitrogen-containing parent heteroaromatic ring that is capable of forming Watson-Crick hydrogen bonds with a complementary nucleobase or nucleobase analog. Exemplary nucleobase analogs include, but are not limited to, 7-deazaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O⁶-methyl guanine, N⁶-methyl adenine, O⁴-methyl thymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine. Additional exemplary nucleobase analogs can be found in Fasman, 1989, Practical Handbook of Biochemistry and Molecular Biology, pp. 385-394, CRC Press, Boca Raton, Fla., and the references cited therein, incorporated herein by reference.
• As used herein, the term “nucleomonomer” means a moiety comprising (1) a base covalently linked to (2) a second moiety. Nucleomonomers can be linked to form oligomers that bind to target or complementary base sequences in nucleic acids in a sequence specific manner. Nucleomonomers may be nucleosides, nucleotides, non-nucleotides or non-nucleosides (e.g. hydroxymethyl substituted nucleomonomer).
• As used herein, the terms “hydroxymethyl substituted nucleomonomer”, “hydroxymethyl nucleomonomer”, “hydroxymethyl monomer”, “acyclic nucleomonomer”, “acyclic monomer”, “acyclic hydroxymethyl substituted nucleomonomer” may be used interchangeably throughout.
• As used herein, the terms “conformationally restricted nucleomonomer”, “conformationally restricted nucleotide” may be used interchangeably and refer to a nucleomonomer that has a bicyclic sugar moiety (e.g. bicyclic ribose) wherein the C2′ and C4′ of the sugar moiety are bridged (e.g., Monomer R) or the C3′ and C5′ are bridged (e.g., Monomer Q). Additional examples may be found in U.S. Pat. No. 6,833,361; U.S. Pat. No. 6,403,566 and U.S. Pat. No. 6,083,482, which are hereby incorporated by reference in their entirety.
• As used herein, the terms “RISC length” or “RISC length RNA complex” means a nucleic acid molecule having less than 25 base pairs.
• As used herein the terms “Dicer length” or “Dicer length RNA complex” means a nucleic acid molecule have 25 or more base pairs, generally, from 25 to 40 base pairs.
• As used herein the term “bifunctional nucleic acid compound” or “bifunctional RNA complex” or “bifunctional dsRNA” means a nucleic acid compound having a sense strand and antisense strand, wherein the sense strand and the antisense strand are each complementary to different regions of the same target RNA (i.e., a first region and a second region), or are each complementary to a region of at least two different target RNAs.
• As used herein, the terms “seed region” or “seed sequence” refer to the region of a microRNA that is implicated in gene regulation by inhibition of translation and/or mRNA degradation, or the portion of the guide strand in a siRNA that is analogous to the seed region of a microRNA.
• As used herein, the term “isolated” means that the referenced material (e.g., nucleic acid molecules of the instant disclosure), is removed from its original environment, such as being separated from some or all of the co-existing materials in a natural environment (e.g., a natural environment may be a cell).
• As used herein, “complementary” refers to a nucleic acid molecule that can form hydrogen bond(s) with another nucleic acid molecule or itself by either traditional Watson-Crick base pairing or other non-traditional types of pairing (e.g., Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleosides or nucleotides. In reference to the nucleic molecules of the present disclosure, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid molecule to proceed, for example, RNAi activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the nucleic acid molecule (e.g., dsRNA) to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or under conditions in which the assays are performed in the case of in vitro assays (e.g., hybridization assays). Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al.,CSH Symp. Quant. Biol. LII:123, 1987; Frier et al.,Proc. Nat'l. Acad. Sci. USA83:9373, 1986; Turner et al.,J. Am. Chem. Soc.109:3783, 1987). Thus, “complementary” or “specifically hybridizable” or “specifically binds” are terms that indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between a nucleic acid molecule (e.g., dsRNA) and a DNA or RNA target. It is understood in the art that a nucleic acid molecule need not be 100% complementary to a target nucleic acid sequence to be specifically hybridizable or to specifically bind. That is, two or more nucleic acid molecules may be less than fully complementary and is indicated by a percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds with a second nucleic acid molecule.
• For example, a first nucleic acid molecule may have 10 nucleotides and a second nucleic acid molecule may have 10 nucleotides, then base pairing of 5, 6, 7, 8, 9, or 10 nucleotides between the first and second nucleic acid molecules, which may or may not form a contiguous double-stranded region, represents 50%, 60%, 70%, 80%, 90%, and 100% complementarity, respectively. In certain embodiments, complementary nucleic acid molecules may have wrongly paired bases—that is, bases that cannot form a traditional Watson-Crick base pair or other non-traditional types of pair (i.e., “mismatched” bases). For instance, complementary nucleic acid molecules may be identified as having a certain number of “mismatches,” such as zero or about 1, about 2, about 3, about 4 or about 5.
• “Perfectly” or “fully” complementary nucleic acid molecules means those in which a certain number of nucleotides of a first nucleic acid molecule hydrogen bond (anneal) with the same number of residues in a second nucleic acid molecule to form a contiguous double-stranded region. For example, two or more fully complementary nucleic acid molecule strands can have the same number of nucleotides (i.e., have the same length and form one double-stranded region, with or without an overhang) or have a different number of nucleotides (e.g., one strand may be shorter than but fully contained within another strand or one strand may overhang the other strand).
• By “ribonucleic acid” or “RNA” is meant a nucleic acid molecule comprising at least one ribonucleotide molecule. As used herein, “ribonucleotide” refers to a nucleotide with a hydroxyl group at the 2′-position of a β-D-ribofuranose moiety. The term RNA includes double-stranded (ds) RNA, single-stranded (ss) RNA, isolated RNA (such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA), altered RNA (which differs from naturally occurring RNA by the addition, deletion, substitution or alteration of one or more nucleotides), or any combination thereof. For example, such altered RNA can include addition of non-nucleotide material, such as at one or both ends of an RNA molecule, internally at one or more nucleotides of the RNA, or any combination thereof. Nucleotides in RNA molecules of the instant disclosure can also comprise non-standard nucleotides, such as naturally occurring nucleotides, non-naturally occurring nucleotides, chemically-modified nucleotides, deoxynucleotides, or any combination thereof. These altered RNAs may be referred to as analogs or analogs of RNA containing standard nucleotides (i.e., standard nucleotides, as used herein, are considered to be adenine, cytidine, guanidine, thymidine, and uridine).
• The term “dsRNA” and “RNA complex” as used herein, refers to any nucleic acid molecule comprising at least one ribonucleotide molecule and capable of inhibiting or down regulating gene expression, for example, by promoting RNA interference (“RNAi”) or gene silencing in a sequence-specific manner. The dsRNAs (mdRNAs) of the instant disclosure may be suitable substrates for Dicer or for association with RISC to mediate gene silencing by RNAi. Examples of dsRNA molecules of this disclosure are provided in the Sequence Listing identified herein. One or both strands of the dsRNA can further comprise a terminal phosphate group, such as a 5′-phosphate or 5′,3′-diphosphate. As used herein, dsRNA molecules, in addition to at least one ribonucleotide, can further include substitutions, chemically-modified nucleotides, and non-nucleotides. In certain embodiments, dsRNA molecules comprise ribonucleotides up to about 100% of the nucleotide positions.
• The nucleic acid compounds disclosed herein may comprise two strands that together constitute an RNA duplex composed of an antisense strand (the antisense strand is also herein referred to as the guide strand or first strand) and a passenger strand (the passenger strand is also herein referred to as the sense strand or second strand), a single stranded RNA molecule (e.g. antisense RNA), a functional RNA (fRNA), or non-coding RNA (ncRNA), such as small temporal RNA (stRNA), microRNA (miRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) and precursor RNAs thereof, an RNAa molecule, a microRNA mimicking molecule is also considered herein as an RNA complex of the disclosure, as is a single stranded antisense molecule that for example is useful for targeting microRNAs.
• In addition, as used herein, the term dsRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example, meroduplex RNA (mdRNA), nicked dsRNA (ndsRNA), gapped dsRNA (gdsRNA), short interfering nucleic acid (siNA), siRNA, micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering substituted oligonucleotide, short interfering modified oligonucleotide, chemically-modified dsRNA, post-transcriptional gene silencing RNA (ptgsRNA), or the like.
• In some respects, dsRNA molecules described herein form a meroduplex RNA (mdRNA) having three or more strands, for example, an ‘A’ (first or antisense) strand, ‘S1’ (second) strand, and ‘S2’ (third) strand in which the ‘S1’ and ‘S2’ strands are complementary to and form base pairs (bp) with non-overlapping regions of the ‘A’ strand (e.g., an mdRNA can have the form of A:S1S2). The 51, S2, or more strands together essentially comprise a sense strand to the ‘A’ strand. The double-stranded region formed by the annealing of the ‘S1’ and ‘A’ strands is distinct from and non-overlapping with the double-stranded region formed by the annealing of the ‘S2’ and ‘A’ strands. An mdRNA molecule is a “gapped” molecule, meaning a “gap” ranging from 0 nucleotides up to about 10 nucleotides. In some embodiments, the A:S1 duplex is separated from the A:S2 duplex by a gap resulting from at least one unpaired nucleotide (up to about 10 unpaired nucleotides) in the ‘A’ strand that is positioned between the A:S1 duplex and the A:S2 duplex and that is distinct from any one or more unpaired nucleotide at the 3′-end of one or more of the ‘A’, ‘S1’, or ‘S2’ strands. In some embodiments, the A:S1 duplex is separated from the A:B2 duplex by a gap of zero nucleotides (i.e., a nick in which only a phosphodiester bond between two nucleotides is broken or missing in the polynucleotide molecule) between the A:S1 duplex and the A:S2 duplex—which can also be referred to as nicked dsRNA (ndsRNA). For example, A:S1S2 may be comprised of a dsRNA having at least two double-stranded regions that combined total about 14 base pairs to about 40 base pairs and the double-stranded regions are separated by a gap of about 0 to about 10 nucleotides, optionally having blunt ends, or A:S1S2 may comprise a dsRNA having at least two double-stranded regions separated by a gap of up to 10 nucleotides wherein at least one of the double-stranded regions comprises between about 5 base pairs and 13 base pairs.
• The term “large double-stranded RNA” (“large dsRNA”) refers to any double-stranded RNA longer than about 40 base pairs (bp) to about 100 bp or more, particularly up to about 300 bp to about 500 bp. The sequence of a large dsRNA may represent a segment of an mRNA or an entire mRNA. A double-stranded structure may be formed by a self-complementary nucleic acid molecule or by annealing of two or more distinct complementary nucleic acid molecule strands.
• In addition, as used herein, the term “RNAi” is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, dsRNA molecules of this disclosure can be used to epigenetically silence genes at the post-transcriptional level or the pre-transcriptional level or any combination thereof.
• As used herein, the term “nucleic acid based regulatory system” or “cell regulatory system dependent upon a nucleic acid” refers to any cell regulatory system that is regulated, modified, controlled, or modulated, in full or part, by the presence and/or function of a nucleomonomer, nucleotide, nucleoside, and/or oligonucleotide.
• As used herein, “target nucleic acid” refers to any nucleic acid sequence whose expression or activity is to be altered. The target nucleic acid can be DNA, RNA, or analogs thereof, and includes single, double, and multi-stranded forms.
• By “target site” or “target sequence” is meant a sequence within a target nucleic acid (e.g., mRNA) that, when present in an RNA molecule, is “targeted” for cleavage by RNAi and mediated by a dsRNA construct of this disclosure containing a sequence within the antisense strand that is complementary to the target site or sequence.
• As used herein, “off-target effect” or “off-target profile” refers to the observed altered expression pattern of one or more genes in a cell or other biological sample not targeted, directly or indirectly, for gene silencing by an mdRNA or dsRNA. For example, an off-target effect can be quantified by using a DNA microarray to determine how many non-target genes have an expression level altered by about two-fold or more in the presence of a candidate mdRNA or dsRNA, or analog thereof specific for a target sequence.
• A “minimal off-target effect” means that an mdRNA or dsRNA affects expression by about two-fold or more of about 25% to about 1% of the non-target genes examined or it means that the off-target effect of substituted or modified mdRNA or dsRNA (e.g., having at least one uridine substituted with a 5-methyluridine or 2-thioribothymidine and optionally having at least one nucleotide modified at the 2′-position), is reduced by at least about 1% to about 80% or more as compared to the effect on non-target genes of an unsubstituted or unmodified mdRNA or dsRNA.
• By “sense region” or “sense strand” or “second strand” is meant one or more nucleotide sequences of a nucleic acid compound having complementarity to one or more antisense regions of the nucleic acid compound. In addition, the sense region of a nucleic acid compound comprises a nucleic acid sequence having homology or identity to a target sequence.
• By “antisense region” or “antisense strand” or “first strand” is meant a nucleotide sequence of a dsRNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a dsRNA molecule can comprise nucleic acid sequence region having complementarity to one or more sense strands of the dsRNA molecule.
• “Analog” as used herein refers to a compound that is structurally similar to a parent compound (e.g., a nucleic acid molecule), but differs slightly in composition (e.g., one atom or functional group is different, added, or removed). The analog may or may not have different chemical or physical properties than the original compound and may or may not have improved biological or chemical activity. For example, the analog may be more hydrophilic or it may have altered activity as compared to a parent compound. The analog may mimic the chemical or biological activity of the parent compound (i.e., it may have similar or identical activity), or, in some cases, may have increased or decreased activity. The analog may be a naturally or non-naturally occurring (e.g., chemically-modified or recombinant) variant of the original compound. An example of an RNA analog is an RNA molecule having a non-standard nucleotide, such as 5-methyuridine or 5-methylcytidine or 2-thioribothymidine, which may impart certain desirable properties (e.g., improve stability, bioavailability, minimize off-target effects or interferon response).
• As used herein, the term “universal base” refers to nucleotide base analogs that form base pairs with each of the standard DNA/RNA bases with little discrimination between them. A universal base is thus interchangeable with all of the standard bases when substituted into a nucleotide duplex (see, e.g., Loakes et al.,J. Mol. Bio.270:426, 1997). Exemplary universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, or nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole (see, e.g., Loakes,Nucleic Acids Res.29:2437, 2001).
• The term “gene” as used herein, especially in the context of “target gene” or “gene target” for RNAi, means a nucleic acid molecule that encodes an RNA or a transcription product of such gene, including a messenger RNA (mRNA, also referred to as structural genes that encode for a polypeptide), an mRNA splice variant of such gene, a functional RNA (fRNA), or non-coding RNA (ncRNA), such as small temporal RNA (stRNA), microRNA (miRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) and precursor RNAs thereof. Such non-coding RNAs can serve as target nucleic acid molecules for dsRNA mediated RNAi to alter the activity of the target RNA involved in functional or regulatory cellular processes.
• As used herein, “gene silencing” refers to a partial or complete loss-of-function through targeted inhibition of gene expression in a cell, which may also be referred to as RNAi “knockdown,” “inhibition,” “down-regulation,” or “reduction” of expression of a target gene. Depending on the circumstances and the biological problem to be addressed, it may be preferable to partially reduce gene expression. Alternatively, it might be desirable to reduce gene expression as much as possible. The extent of silencing may be determined by methods described herein and known in the art (see, e.g., PCT Publication No. WO 99/32619; Elbashir et al.,EMBO J.20:6877, 2001). Depending on the assay, quantification of gene expression permits detection of various amounts of inhibition that may be desired in certain embodiments of this disclosure, including prophylactic and therapeutic methods, which will be capable of knocking down target gene expression, in terms of mRNA level or protein level or activity, for example, by equal to or greater than 10%, 30%, 50%, 75% 90%, 95% or 99% of baseline (i.e., normal) or other control levels, including elevated expression levels as may be associated with particular disease states or other conditions targeted for therapy.
• As used herein, the term “therapeutically effective amount” means an amount of dsRNA that is sufficient to result in a decrease in severity of disease symptoms, an increase in frequency or duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease, in the subject (e.g., human) to which it is administered. For example, a therapeutically effective amount of dsRNA directed against an mRNA of a target gene can inhibit the deposition of lipoproteins in the walls of arteries by at least about 20%, at least about 40%, at least about 60%, or at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can decrease, for example, atheromatous plaque size or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such therapeutically effective amounts based on such factors as the subject's size, the severity of symptoms, and the particular composition or route of administration selected. The nucleic acid molecules of the instant disclosure, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein. For example, to treat a particular disease, disorder, or condition, the dsRNA molecules can be administered to a patient or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs, under conditions suitable for treatment.
• In addition, it should be understood that the individual compounds, or groups of compounds, derived from the various combinations of the structures and substituents described herein, are disclosed by the present application to the same extent as if each compound or group of compounds was set forth individually. Thus, selection of particular structures or particular substituents is within the scope of the present disclosure. As described herein, all value ranges are inclusive over the indicated range. Thus, a range of C₁-C₄will be understood to include the values of 1, 2, 3, and 4, such that C₁, C₂, C₃and C₄are included.
• The term “alkyl” as used herein refers to a saturated, branched or unbranched, substituted or unsubstituted aliphatic group containing from 1-22 carbon atoms (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 carbon atoms). This definition applies to the alkyl portion of other groups such as, for example, alkoxy, alkanoyl, aralkyl, and other groups defined below. The term “cycloalkyl” as used herein refers to a saturated, substituted or unsubstituted cyclic alkyl ring containing from 3 to 12 carbon atoms.
• The term “alkenyl” as used herein refers to an unsaturated, branched or unbranched, substituted or unsubstituted alkyl or cycloalkyl having 2 to 22 carbon atoms and at least one carbon-carbon double bond. The term “alkynyl” as used herein refers to an unsaturated, branched or unbranched, substituted or unsubstituted alkyl or cycloalkyl having 2 to 22 carbon atoms and at least one carbon-carbon triple bond.
• The term “alkoxy” as used herein refers to an alkyl, cycloalkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom. The term “alkanoyl” as used herein refers to —C(═O)-alkyl, which may alternatively be referred to as “acyl.” The term “alkanoyloxy” as used herein refers to —O—C(═O)-alkyl groups. The term “alkylamino” as used herein refers to the group —NRR′, where R and R′ are each either hydrogen or alkyl, and at least one of R and R′ is alkyl. Alkylamino includes groups such as piperidino wherein R and R′ form a ring. The term “alkylaminoalkyl” refers to -alkyl-NRR′.
• The term “aryl” as used herein refers to any stable monocyclic, bicyclic, or polycyclic carbon ring system of from 4 to 12 atoms in each ring, wherein at least one ring is aromatic. Some examples of an aryl include phenyl, naphthyl, tetrahydro-naphthyl, indanyl, and biphenyl. Where an aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is to the aromatic ring. An aryl may be substituted or unsubstituted.
• The term “heteroaryl” as used herein refers to any stable monocyclic, bicyclic, or polycyclic carbon ring system of from 4 to 12 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Some examples of a heteroaryl include acridinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and tetrahydroquinolinyl. A heteroaryl includes the N-oxide derivative of a nitrogen-containing heteroaryl.
• The term “heterocycle” or “heterocyclyl” as used herein refers to an aromatic or nonaromatic ring system of from five to twenty-two atoms, wherein from 1 to 4 of the ring atoms are heteroatoms selected from oxygen, nitrogen, and sulfur. Thus, a heterocycle may be a heteroaryl or a dihydro or tetrathydro version thereof.
• The term “aroyl” as used herein refers to an aryl radical derived from an aromatic carboxylic acid, such as a substituted benzoic acid. The term “aralkyl” as used herein refers to an aryl group bonded to an alkyl group, for example, a benzyl group.
• The term “carboxyl” as used herein represents a group of the formula —C(═O)OH or —C(═O)O⁻. The terms “carbonyl” and “acyl” as used herein refer to a group in which an oxygen atom is double-bonded to a carbon atom >C═O. The term “hydroxyl” as used herein refers to —OH or —O⁻. The term “nitrile” or “cyano” as used herein refers to —CN. The term “halogen” or “halo” refers to fluoro (—F), chloro (—Cl), bromo (—Br), and iodo (—I).
• The term “cycloalkyl” as used herein refers to a saturated cyclic hydrocarbon ring system containing from 3 to 12 carbon atoms that may be optionally substituted. Exemplary embodiments include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In certain embodiments, the cycloalkyl group is cyclopropyl. In another embodiment, the (cycloalkyl)alkyl groups contain from 3 to 12 carbon atoms in the cyclic portion and 1 to 6 carbon atoms in the alkyl portion. In certain embodiments, the (cycloalkyl)alkyl group is cyclopropylmethyl. The alkyl groups are optionally substituted with from one to three substituents selected from the group consisting of halogen, hydroxy and amino.
• The terms “alkanoyl” and “alkanoyloxy” as used herein refer, respectively, to —C(O)-alkyl groups and —O—C(═O)— alkyl groups, each optionally containing 2 to 10 carbon atoms. Specific embodiments of alkanoyl and alkanoyloxy groups are acetyl and acetoxy, respectively.
• The term “alkynyl” as used herein refers to an unsaturated branched, straight-chain, or cyclic alkyl group having 2 to 10 carbon atoms and having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Exemplary alkynyls include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 4-pentynyl, 1-octynyl, 6-methyl-1-heptynyl, 2-decynyl, or the like. The alkynyl group may be substituted or unsubstituted.
• The term “hydroxyalkyl” alone or in combination, refers to an alkyl group as previously defined, wherein one or several hydrogen atoms, preferably one hydrogen atom has been replaced by a hydroxyl group. Examples include hydroxymethyl, hydroxyethyl and 2-hydroxyethyl.
• The term “aminoalkyl” as used herein refers to the group —NRR′, where R and R′ may independently be hydrogen or (C₁-C₄) alkyl.
• The term “alkylaminoalkyl” refers to an alkylamino group linked via an alkyl group (i.e., a group having the general structure -alkyl-NH-alkyl or -alkyl-N(alkyl)(alkyl)). Such groups include, but are not limited to, mono- and di-(C₁-C₈alkyl)aminoC₁-C₈alkyl, in which each alkyl may be the same or different.
• The term “dialkylaminoalkyl” refers to alkylamino groups attached to an alkyl group. Examples include, but are not limited to, N,N-dimethylaminomethyl, N,N-dimethylaminoethyl N,N-dimethylaminopropyl, and the like. The term dialkylaminoalkyl also includes groups where the bridging alkyl moiety is optionally substituted.
• The term “haloalkyl” refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, or the like.
• The term “carboxyalkyl” as used herein refers to the substituent —R¹⁰—COOH, wherein R¹⁰is alkylene; and “carbalkoxyalkyl” refers to —R¹⁰—C(O)OR¹¹, wherein R¹⁰and R¹¹are alkylene and alkyl respectively. In certain embodiments, alkyl refers to a saturated straight- or branched-chain hydrocarbyl radical of 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 2-methylpentyl, n-hexyl, and so forth. Alkylene is the same as alkyl except that the group is divalent.
• The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. In one embodiment, the alkoxy group contains 1 to about 10 carbon atoms. Embodiments of alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Embodiments of substituted alkoxy groups include halogenated alkoxy groups. In a further embodiment, the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Exemplary halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.
• The term “alkoxyalkyl” refers to an alkylene group substituted with an alkoxy group. For example, methoxyethyl (CH₃OCH₂CH₂—) and ethoxymethyl (CH₃CH₂OCH₂—) are both C₃alkoxyalkyl groups.
• The term “aroyl,” as used alone or in combination herein, refers to an aryl radical derived from an aromatic carboxylic acid, such as optionally substituted benzoic or naphthoic acids.
• The term “aralkyl” as used herein refers to an aryl group bonded to the 2-pyridinyl ring or the 4-pyridinyl ring through an alkyl group, preferably one containing 1 to 10 carbon atoms. A preferred aralkyl group is benzyl.
• The term “carboxy,” as used herein, represents a group of the formula —C(═O)OH or —C(═O)O⁻.
• The term “carbonyl” as used herein refers to a group in which an oxygen atom is double-bonded to a carbon atom —C═O.
• The term “trifluoromethyl” as used herein refers to —CF₃.
• The term “trifluoromethoxy” as used herein refers to —OCF₃.
• The term “hydroxyl” as used herein refers to —OH or —O⁻.
• The term “nitrile” or “cyano” as used herein refers to the group —CN.
• The term “nitro,” as used herein alone or in combination refers to a —NO₂group.
• The term “amino” as used herein refers to the group —NR⁹R⁹, wherein R⁹may independently be hydrogen, alkyl, aryl, alkoxy, or heteroaryl. The term “aminoalkyl” as used herein represents a more detailed selection as compared to “amino” and refers to the group —NR′R′, wherein R′ may independently be hydrogen or (C₁-C₄) alkyl. The term “dialkylamino” refers to an amino group having two attached alkyl groups that can be the same or different.
• The term “alkanoylamino” refers to alkyl, alkenyl or alkynyl groups containing the group —C(═O)— followed by —N(H)—, for example acetylamino, propanoylamino and butanoylamino and the like.
• The term “carbonylamino” refers to the group —NR′—CO—CH₂—R′, wherein R′ may be independently selected from hydrogen or (C₁-C₄) alkyl.
• The term “carbamoyl” as used herein refers to —O—C(O)NH₂.
• The term “carbamyl” as used herein refers to a functional group in which a nitrogen atom is directly bonded to a carbonyl, i.e., as in —NR″C(═O)R″ or —C(═O)NR″R″, wherein R″ can be independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, cycloalkyl, aryl, heterocyclo, or heteroaryl.
• The term “alkylsulfonylamino” refers to the group —NHS(O)₂R¹², wherein R¹²is alkyl.
• The term “halogen” as used herein refers to bromine, chlorine, fluorine or iodine. In one embodiment, the halogen is fluorine. In another embodiment, the halogen is chlorine.
• The term “heterocyclo” refers to an optionally substituted, unsaturated, partially saturated, or fully saturated, aromatic or nonaromatic cyclic group that is a 4 to 7 membered monocyclic, or 7 to 11 membered bicyclic ring system that has at least one heteroatom in at least one carbon atom-containing ring. The substituents on the heterocyclo rings may be selected from those given above for the aryl groups. Each ring of the heterocyclo group containing a heteroatom may have 1, 2, or 3 heteroatoms selected from nitrogen, oxygen or sulfur. Plural heteroatoms in a given heterocyclo ring may be the same or different.
• Exemplary monocyclic heterocyclo groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, tetrahydrofuryl, thienyl, piperidinyl, piperazinyl, azepinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, dioxanyl, triazinyl and triazolyl. Preferred bicyclic heterocyclo groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, benzimidazolyl, benzofuryl, indazolyl, benzisothiazolyl, isoindolinyl and tetrahydroquinolinyl. In more detailed embodiments heterocyclo groups may include indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl and pyrimidyl.
• The “percent identity” between two or more nucleic acid sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical positions/total number of positions×100), taking into account the number of gaps, and the length of each gap that needs to be introduced to optimize alignment of two or more sequences. The comparison of sequences and determination of percent identity between two or more sequences can be accomplished using a mathematical algorithm, such as BLAST and Gapped BLAST programs at their default parameters (e.g., BLASTN, see Altschul et al.,J. Mol. Biol.215:403-410, 1990).
• “Aptamer” or “nucleic acid aptamer” as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule wherein the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art (see, e.g., Gold et al.,Annu. Rev. Biochem.64:763, 1995; Brody and Gold,J. Biotechnol.74:5, 2000; Sun,Curr. Opin. Mol. Ther.2:100, 2000; Kusser,J. Biotechnol.74:27, 2000; Hermann and Patel,Science287:820, 2000; and Jayasena,Clinical Chem.45:1628, 1999).
• The term “substituted” as used herein refers to an atom having one or more substitutions or substituents which can be the same or different and may include a hydrogen substituent. Thus, the terms alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, alkylamino, alkylaminoalkyl, aryl, heteroaryl, heterocycle, aroyl, and aralkyl as used herein refer to groups which include substituted variations. Substituted variations include linear, branched, and cyclic variations, and groups having a substituent or substituents replacing one or more hydrogens attached to any carbon atom of the group. Substituents that may be attached to a carbon atom of the group include alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, alkylamino, alkylaminoalkyl, aryl, heteroaryl, heterocycle, aroyl, aralkyl, acyl, hydroxyl, cyano, halo, haloalkyl, amino, aminoacyl, alkylaminoacyl, acyloxy, aryloxy, aryloxyalkyl, mercapto, nitro, carbamyl, carbamoyl, and heterocycle. For example, the term ethyl includes without limitation —CH₂CH₃, —CHFCH₃, —CF₂CH₃, —CHFCH₂F, —CHFCHF₂, —CHFCF₃, —CF₂CH₂F, —CF₂CHF₂, —CF₂CF₃, and other variations as described above. Representative substituents include —X, —Rd, —O—, ═O, —OR, —SR⁶, —S—, ═S, —NR⁶R⁶, ═NR⁶, —CX₃, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, ═N₂, —N₃, —S(═O)₂O—, —S(═O)₂OH, —S(═O)₂R⁶, —OS(═O)₂O—, —OS(═O)₂OH, —OS(═O)₂R⁶, —P(═O)(O)₂, —P(═O)(OH)(O⁻), —OP(═O)₂(O⁻), —C(—O)R⁶, —C(═S)R⁶, —C(═O)OR⁶, —C(═O)O⁻, —C(═S)OR⁶, —NR⁶—C(═O)—N(R⁶)₂, —NR⁶—C(═S)—N(R⁶)₂, and —C(═NR⁶)NR⁶R⁶, wherein each X is independently a halogen; and each R⁶is independently hydrogen, halogen, alkyl, aryl, arylalkyl, arylaryl, arylheteroalkyl, heteroaryl, heteroarylalkyl, NR⁷R⁷, —C(═O)R⁷, and —S(═O)₂R⁷; and each R⁷is independently hydrogen, alkyl, alkanyl, alkynyl, aryl, arylalkyl, arylheteralkyl, arylaryl, heteroaryl or heteroarylalkyl. Aryl containing substituents, whether or not having one or more substitutions, may be attached in a para (p-), meta (m-) or ortho (o-) conformation, or any combination thereof. In general, substituents may be further substituted with any atom or group of atoms.
• For example purposes only, the position of a nucleomonomer in a strand may be described as follows where X represents any type of nucleomonomer (e.g., nucleoside, modified nucleotide, RNA, DNA, hydroxymethyl substituted nucleomonomer or conformationally restricted nucleomonomer) and the number represents the position of that nucleomonomer in the strand. For example, X1 represents position one of the strand below counting from the 5′-end of the strand; X7 represents position seven of the strand below counting from the 5′-end of the strand. Alternatively, X1, X2, and X3 represent the last three positions at the 5′-end of the strand below, and X1 to X10 represent the last ten positions at the 5′-end of the strand. The X_nmay represent positions 11 to 60 (or n=1 to 60), thus when n is 20 (or X20), this indicates position 20 of the strand counting from the 5′-end of the strand.
• 
  5′ X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X_n3′
• The same approach may be taken by counting from the 3′-end of a strand in order to identify the position of a nucleomonomer in the strand (example strand shown below). For the strand below, the position of a nucleomonomer in the strand may be described as follows where X represents any type of nucleomonomer (e.g., nucleoside, modified nucleotide, RNA, DNA, hydroxymethyl substituted nucleomonomer or conformationally restricted nucleomonomer) and the number represents the position of that nucleomonomer in the strand. For example, X1 represents position one of the strand below counting from the 3′-end of the strand; X7 represents position seven of the strand below counting from the 3′-end of the strand. Alternatively, X1, X2, and X3 represent the last three positions at the 3′-end of the strand below, and X1 to X10 represent the last ten positions at the 3′-end of the strand. The X_nmay represent positions 11 to 60 (or n=1 to 60), thus when n is 20 (or X20), this indicates position 20 of the strand counting from the 3′-end of the strand.
• 
  5′ X_n-X10-X9-X8-X7-X6-X5-X4-X3-X2-X1 3′
• All publications, non-patent publications, references, patents, patent publications, patent applications and other literature cited herein are each hereby specifically incorporated by reference in entirety.
• While this disclosure has been described in relation to certain embodiments, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that this disclosure includes additional embodiments, and that some of the details described herein may be varied considerably without departing from this disclosure. This disclosure includes such additional embodiments, modifications and equivalents. In particular, this disclosure includes any combination of the features, terms, or elements of the various illustrative components and examples.
• The use herein of the terms “a,” “an,” “the” and similar terms in describing the disclosure, and in the claims, are to be construed to include both the singular and the plural.
• The terms “comprising,” “having,” “including” and “containing” are to be construed as open-ended terms which mean, for example, “including, but not limited to.” Thus, terms such as “comprising,” “having,” “including” and “containing” are to be construed as being inclusive, not exclusive.
• Recitation of a range of values herein refers individually to each and any separate value falling within the range as if it were individually recited herein, whether or not some of the values within the range are expressly recited. For example, the range “4 to 12” includes without limitation the values 5, 5.1, 5.35 and any other whole, integer, fractional, or rational value greater than or equal to 4 and less than or equal to 12. Specific values employed herein will be understood as exemplary and not to limit the scope of the disclosure.
• Recitation of a range of number of carbon atoms herein refers individually to each and any separate value falling within the range as if it were individually recited herein, whether or not some of the values within the range are expressly recited. For example, the term “C_1-24” includes without limitation the species C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, and C24.
• Definitions of technical terms provided herein should be construed to include without recitation those meanings associated with these terms known to those skilled in the art, and are not intended to limit the scope of the disclosure. Definitions of technical terms provided herein shall be construed to dominate over alternative definitions in the art or definitions which become incorporated herein by reference to the extent that the alternative definitions conflict with the definition provided herein.
• The examples given herein, and the exemplary language used herein are solely for the purpose of illustration, and are not intended to limit the scope of the disclosure.
• When a list of examples is given, such as a list of compounds or molecules suitable for this disclosure, it will be apparent to those skilled in the art that mixtures of the listed compounds or molecules are also suitable.
EXAMPLESExample 1RNA Targeting Survivin (BIRC5)
• Sequence specific RNAs targeting Survivin (BIRC5) are shown in Tables 1 and 2. CRN monomers in the sequences of Tables 1 and 2 are identified as “crnX” where X is the one letter code for the nucleotide: A, U, C or G. For example, “crnC” indicates a cytidine CRN. The CRN in Tables 1 and 2 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:1-80 will complex with one of the antisense sequences SEQ ID NOs:81-160, respectively, in other words, SEQ ID NO:1 will complex with SEQ ID NO:81, SEQ ID NO:2 will complex with SEQ ID NO:82, and so forth.

• TABLE 1
  RNA Targeting Survivin

  SEQ ID NO:	Sense Sequence (5′ to 3′ left to right)

  1	CUGCCUGGCAGCCCUUUCcrnU
  2	CcrnUGCCUGGCAGCCCUUUCUUcrnU
  3	crnUcrnCUGCCUGGCAGCCCUUUCUUcrnU
  4	CcrnUcrnGCCUGGCAGCCCUUUCUUcrnU
  5	CUGCCUGGCAGCCCUUUCcrnUUU
  6	CcrnUGCCUGGCAGCCCUUUCcrnUUU
  7	crnCcrnUGCCUGGCAGCCCUUUCcrnUUU
  8	UcrnCcrnUGCCUGGCAGCCCUUUCcrnUUU
  9	GACCACCGCAUCUCUAcrnCAcrnU
  10	GcrnACCACCGCAUCUCUACAcrnUUcrnU
  11	crnUcrnGACCACCGCAUCUCUACAcrnUUcrnU
  12	GcrnAcrnCCACCGCAUCUCUACAcrnUUcrnU
  13	GACCACCGCAUCUCUACAcrnUcrnUcrnU
  14	GcrnACCACCGCAUCUCUACAcrnUcrnUcrnU
  15	crnGcrnACCACCGCAUCUCUACAcrnUcrnUcrnU
  16	UcrnGcrnACCACCGCAUCUCUACAcrnUcrnUcrnU
  17	CGCAUCUCUACAUUCAAGA
  18	CGCAUCUCUACAUUCAAGAUU
  19	UCGCAUCUCUACAUUCAAGAUU
  20	CGCAUCUCUACAUUCAAGAUU
  21	CGCAUCUCUACAUUCAAGAUU
  22	CGCAUCUCUACAUUCAAGAUU
  23	CGCAUCUCUACAUUCAAGAUU
  24	UCGCAUCUCUACAUUCAAGAUU
  25	GCCCAGUGUUUCUUCUGCU
  26	GCCCAGUGUUUCUUCUGCUUU
  27	UGCCCAGUGUUUCUUCUGCUUU
  28	GCCCAGUGUUUCUUCUGCUUU
  29	GCCCAGUGUUUCUUCUGCUUU
  30	GCCCAGUGUUUCUUCUGCUUU
  31	GCCCAGUGUUUCUUCUGCUUU
  32	UGCCCAGUGUUUCUUCUGCUUU
  33	CcrnCCcrnAGcrnUGcrnUUcrnUCcrnUUcrnCU
  	crnGCcrnUU
  34	CCcrnCAGcrnUGUcrnUUCcrnUUCcrnUGCcrn
  	UUUcrnU
  35	UCCcrnCAGUcrnGUUUcrnCUUCcrnUGCUcrnUUU
  36	CCCAcrnGUGUUcrnUCUUCcrnUGCUUcrnUU
  37	CCCAGcrnUGUUUCcrnUUCUGCcrnUUUU
  38	CCCAGUcrnGUUUCUUcrnCUGCUUUcrnU
  39	CCCAGUGcrnUUUCUUCUcrnGCUUUU
  40	UCCCAGUGcrnUUUCUUCUGcrnCUUUU
  41	CCAGUGUUUcrnCUUCUGCUUC
  42	CCAGUGUUUcrnCcrnUUCUGCUUCUU
  43	UCCAGUGUUcrnUCUcrnUCUGCUUCUU
  44	CCAGUGcrnUcrnUcrnUCUUCUGCUUCUU
  45	CCAGUGUcrnUcrnUCUUCUGCUUCUU
  46	CCAGUGUUcrnUcrnCUUCUGCUUCUU
  47	CCAGUGUcrnUUcrnCUUCUGCUUCUU
  48	UCCAGUGUcrnUUCcrnUUCUGCUUCUU
  49	CAGUGUUUCUUCUGCUcrnUCA
  50	CcrnAGUGUUUCUUCUGCUUCAUcrnU
  51	crnUcrnCAGUGUUUCUUCUGCUUCcrnAUcrnU
  52	CcrnAcrnGUGUUUCUUCUGCUUCcrnAcrnUcrnU
  53	crnCAGUGUUUCUUCUGCUUCAUU
  54	CAcrnGUGUUUCUUCUGCUUCAcrnUU
  55	crnCAcrnGUGUUUCUUCUGCUUCcrnAcrnUU
  56	crnUcrnCcrnAGUGUUUCUUCUGCUUCAcrnUcrnU
  57	AGUGUUUCcrnUcrnUCUGCUUCAA
  58	AGUGUUUCcrnUcrnUCUGCUUCAAUU
  59	UAGUGUUUCcrnUcrnUCUGCUUCAAUU
  60	AGUGUUUcrnCUcrnUCcrnUGCUUCAAUU
  61	AGUGUUUCcrnUUCcrnUGCUUCAAUU
  62	AGUGUUUCUcrnUCUGcrnCUUCAAUU
  63	AGUGUUUCUUcrnCUGcrnCUUcrnCAAUU
  64	UAGUGUUUcrnCUUcrnCUGcrnCUUCAAUU
  65	GAAGAcrnAAGAAUUUcrnGAGGAA
  66	GAAGAAAGAAUUUGAGGAAUU
  67	UGcrnAAGAAAGAAUUUGAGGcrnAAUU
  68	GAcrnAGAAcrnAGAAUUUGAGGAAUcrnU
  69	GAAGcrnAAAGAAUUcrnUGAGGAAUcrnU
  70	GAAGAAAGAAUUUGAGGAAcrnUcrnU
  71	crnGcrnAcrnAcrnGcrnAAAGAAUUUGAGGAAUU
  72	UGAAcrnGAAAcrnGAAUUUGAGGAAUU
  73	AGUGGCcrnACCAGcrnAGGUGCUcrnU
  74	crnAGUGGCACCAGAGGUGCUUUcrnU
  75	crnUAGUGGCACCAGAGGUGCUcrnUUcrnU
  76	AGUGGCACCAGAGGUGCUUcrnUcrnU
  77	crnAGUGGcrnCACCAGAGGUGCUUUU
  78	AGUGGCACCAGAGGUGCcrnUUUU
  79	AGUGGCACCAGAGGUGCUUcrnUU
  80	UAGUGGCACCAGAGGUGCUUUcrnU

• TABLE 2
  RNA Targeting Survivin

  SEQ ID NO:	Antisense Sequence (5′ to 3′)

  81	AGAAAGGGCUGCCAGGCAG
  82	AGAAAGGGCUGCCAGGCAGUU
  83	AGAAAGGGCUGCCAGGCAGUU
  84	AGAAAGGGCUGCCAGGCAGUU
  85	AGAAAGGGCUGCCAGGCAGUU
  86	AGAAAGGGCUGCCAGGCAGUU
  87	AGAAAGGGCUGCCAGGCAGUU
  88	AGAAAGGGCUGCCAGGCAGUU
  89	AUGUAGAGAUGCGGUGGUC
  90	AUGUAGAGAUGCGGUGGUCUU
  91	AUGUAGAGAUGCGGUGGUCUU
  92	AUGUAGAGAUGCGGUGGUCUU
  93	AUGUAGAGAUGCGGUGGUCUU
  94	AUGUAGAGAUGCGGUGGUCUU
  95	AUGUAGAGAUGCGGUGGUCUU
  96	AUGUAGAGAUGCGGUGGUCUU
  97	crnUCUUGAAUGUAGAGAUGCG
  98	UCcrnUUGAAUGUAGAGAUGCGUU
  99	crnUCcrnUUGAAUGUAGAGAUGCGUU
  100	crnUcrnCcrnUUGAAUGUAGAGAUGCGUU
  101	crnUCUUGAAUGUAGAGAUGCGcrnUU
  102	UCcrnUUGAAUGUAGAGAUGCGcrnUU
  103	crnUCcrnUUGAAUGUAGAGAUGCGcrnUU
  104	crnUcrnCcrnUUGAAUGUAGAGAUGCGcrnUU
  105	crnAGCAGAAGAAACACUGcrnGcrnGC
  106	AGcrnCAGAAGAAACACUGGGcrnCcrnUU
  107	crnAGcrnCAGAAGAAACACUGGGcrnCcrnUU
  108	crnAcrnGcrnCAGAAGAAACACUGGGcrnCcrnUU
  109	crnAGCAGAAGAAACACUGGGCcrnUcrnU
  110	AGcrnCAGAAGAAACACUGGGCcrnUcrnU
  111	crnAGcrnCAGAAGAAACACUGGGCcrnUcrnU
  112	crnAcrnGcrnCAGAAGAAACACUGGGCcrnUcrnU
  113	AAGCAGAAGAAACACUGGG
  114	AAGCAGAAGAAACACUGGGUU
  115	AAGCAGAAGAAACACUGGGUU
  116	AAGCAGAAGAAACACUGGGUU
  117	AAGCAGAAGAAACACUGGGUU
  118	AAGCAGAAGAAACACUGGGUU
  119	AAGCAGAAGAAACACUGGGUU
  120	AAGCAGAAGAAACACUGGGUU
  121	GAAGCAGAAGAAACACUGG
  122	GAAGCAGAAGAAACACUGGUU
  123	GAAGCAGAAGAAACACUGGUU
  124	GAAGCAGAAGAAACACUGGUU
  125	GAAGCAGAAGAAACACUGGUU
  126	GAAGCAGAAGAAACACUGGUU
  127	GAAGCAGAAGAAACACUGGUU
  128	GAAGCAGAAGAAACACUGGUU
  129	UGAAGCAGAAGAAACAcrnCUG
  130	UcrnGAAGCAGAAGAAACACUGUcrnU
  131	crnUcrnGAAGCAGAAGAAACACUcrnGUcrnU
  132	UcrnGcrnAAGCAGAAGAAACACUcrnGcrnUcrnU
  133	crnUGAAGCAGAAGAAACACUGUU
  134	UGcrnAAGCAGAAGAAACACUGcrnUU
  135	crnUGcrnAAGCAGAAGAAACACUcrnGcrnUU
  136	crnUcrnGcrnAAGCAGAAGAAACACUGcrnUcrnU
  137	UUGAAGCcrnAcrnGcrnAAGAAACACU
  138	UUGAAGCAcrnGcrnAcrnAGAAACACUUU
  139	UUGAAGCAcrnGcrnAAGAAACACUUU
  140	UUGAAGCcrnAGcrnAAcrnGAAACACUUU
  141	UUGAAGCAcrnGAAcrnGAAcrnACACUUU
  142	UUGAAGCcrnAGAAcrnGAAACACUUU
  143	UUGAAGCAcrnGAAcrnGAAcrnACACUUU
  144	UUGAAGCAGcrnAAGAAACACUUU
  145	UUCCUCAAAUUCUUUCUUC
  146	UUCCUCAAAUUCUUUCUUCUU
  147	UUCCUCAAAUUCUUUCUUCUU
  148	UUCCUCAAAUUCUUUCUUCUU
  149	UUCCUCAAAUUCUUUCUUCUU
  150	UUCCUCAAAUUCUUUCUUCUU
  151	UUCCUCAAAUUCUUUCUUCUU
  152	UUCCUCAAAUUCUUUCUUCUU
  153	AAGCACCUCUGGUGCCACU
  154	AAGCACCUCUGGUGCCACUUU
  155	AAGCACCUCUGGUGCCACUUU
  156	AAGCACCUCUGGUGCCACUUU
  157	AAGCACCUCUGGUGCCACUUU
  158	AAGCACCUCUGGUGCCACUUU
  159	AAGCACCUCUGGUGCCACUUU
  160	AAGCACCUCUGGUGCCACUUU

Example 2RNA Targeting PLK
• Sequence specific RNAs targeting PLK1 are shown in Tables 3 and 4. CRN monomers in the sequences of Tables 3 and 4 are identified as “crnX” where X is the one letter code for the nucleobase: A, U, C or G. For example, “crnC” indicates a cytosine CRN. The CRN in Tables 3 and 4 is based on Monomer Q, Monomer R, or a combination of Monomers R and Q. In some embodiments, The CRN in Tables 3 and 4 is based on Monomer R. Each one of sense sequences SEQ ID NOs:161-190 will complex with one of the antisense sequences SEQ ID NOs:191-220, respectively, in other words, SEQ ID NO:161 will complex with SEQ ID NO:191, SEQ ID NO:162 will complex with SEQ ID NO:192, and so forth. “d” refers to “deoxy.”

• TABLE 3
  RNA Targeting PLK1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  161	GAGGUCCUAGUGGACCCACGCAcrnGCC
  162	AcrnGGUCCUAGUGGACCCACGCAGCCcrnG
  163	crnCcrnCUAGUGGACCCACGCAGCCGGcrnCGcrnG
  164	GcrnUcrnGGACCCACGCAGCCGGCGGCGcrnCcrnU
  165	CUCCUGGAGCUGCACAAGAGGAGcrnGcrnA
  166	CCcrnUGGAGCUGCACAAGAGGAGGAcrnAA
  167	crnGGCUGCCAGUACCUGCACCGAAcrnAcrnCC
  168	GACCUCAAGCUGGGCAACCUUUUcrnCcrnC
  169	GCCUAAAAGAGACCUACCUCCGGAU
  170	ACCUACCUCCGGAUCAAGAAGAAUG
  171	AUACAGUAUUCCCAAGCACAUCAAC
  172	GCCUCCCUCAUCCAGAAGAUGCUUC
  173	AGAAGAUGCUUCAGACAGAUCCCAC
  174	UCUUCUGGGUCAGCAAGUGGGUGGA
  175	CAGCCUGCAGUACAUAGAGCGUGAC
  176	CUGCAGUACAUAGAGCGUGACGGCA
  177	CCcrnUUcrnGAcrnUGcrnAAcrnGAcrnAGcrnAUcrnCAcrnCCcrnCUcrnCCU
  178	UAUcrnUUCcrnCGCcrnAAUcrnUACcrnAUGcrnAGCcrnGAGcrnC
  179	GCCCcrnGGCUcrnGCCCcrnUACCcrnUACGcrnGACCcrnU
  180	GCCAUcrnCAUCCcrnUGCACcrnCUCAGcrnCAACG
  181	crnCcrnCUUGAUGAAGAAGAUCACdTdT
  182	UUACAGUcrnAcrnUcrnUCCCAAGCACAUU
  183	UACAGUAUcrnUCcrnCCAAGCACAUUU
  184	UACCUCAAGcrnCcrnUGcrnGGCAACCUUU
  185	UCCcrnUCAAcrnGCUcrnGGGCAACCUUUU
  186	UAAUACAGUAUUCCCAAGcrnCAcrnUcrnU
  187	UAGcrnAcrnAGAUGCUUCAGACAGAUU
  188	crnUcrnUcrnCCUUGAUGAAGAAGAUCAUU
  189	crnUcrnCCUUGAUGAAGAAGAUCACcrnUcrnU
  190	crnUAUUUCCGCAAUUACAUGAGUcrnU

• TABLE 4
  RNA Targeting PLK1

  SEQ
  ID NO:	Antisense Sequence (5′ to 3′)
  191	GGCUGCGUGGGUCCACUAGGACCUCCG
  192	CGGCUGCGUGGGUCCACUAGGACCUCC
  193	CCGCCGGCUGCGUGGGUCCACUAGGAC
  194	AGCGCCGCCGGCUGCGUGGGUCCACUA
  195	UCCUCCUCUUGUGCAGCUCCAGGAGAG
  196	UUUCCUCCUCUUGUGCAGCUCCAGGAG
  197	GGUUUCGGUGCAGGUACUGGCAGCCAA
  198	GGAAAAGGUUGCCCAGCUUGAGGUCUC
  199	AUCCGGAGGUAGGUCUCUUUUAGGcrnCAA
  200	CcrnAUUCUUCUUGAUCCGGAGGUAGGUCcrnU
  201	crnGcrnUUGAUGUGCUUGGGAAUACUGUAcrnUUcrnC
  202	GcrnAcrnAGCAUCUUCUGGAUGAGGGAGGcrnCcrnGcrnG
  203	crnGUGGGAUCUGUCUGAAGCAUCUUCUGG
  204	UCcrnCACCCACUUGCUGACCCAGAAGAcrnUG
  205	crnGUcrnCACGCUCUAUGUACUGCAGGCUcrnGcrnUC
  206	crnUcrnGcrnCCGUCACGCUCUAUGUACUGCAGcrnGcrnC
  207	AGGAGGGUGAUCUUCUUCAUCAAGGAG
  208	GCUCGCUCAUGUAAUUGCGGAAAUAUU
  209	AGGUCCGUAGGUAGGGCAGCCGGGCGA
  210	CGUUGCUGAGGUGCAGGAUGAUGGCGC
  211	GUGAUCUUCUUCAUCAAGGdTdT
  212	UGUGCUUGGGAAUACUGUAUU
  213	AUGUGCUUGGGAAUACUGUUU
  214	AGGUUGCCCAGCUUGAGGUUU
  215	AAGGUUGCCCAGCUUGAGGUU
  216	UGCUUGGGAAUACUGUAUUUU
  217	UCUGUCUGAAGCAUCUUCUUU
  218	UGAUCUUCUUCAUCAAGGAUU
  219	crnGcrnUcrnGAUCUUCUUCAUCAAGGUU
  220	CUCAUGUAAUUGCGGAAAcrnUcrnUcrnU

Example 3RNA Targeting AKT1-1
• Sequence specific RNAs targeting AKT1-1 are shown in Tables 5 and 6. The CRN in Tables 5 and 6 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. In some embodiments, the CRN in Tables 5 and 6 is based on Monomer Q. Each one of sense sequences SEQ ID NOs:221-225 will complex with one of the antisense sequences SEQ ID NOs:226-230, respectively, in other words, SEQ ID NO:221 will complex with SEQ ID NO:226, SEQ ID NO:222 will complex with SEQ ID NO:227, and so forth.

• TABLE 5
  RNA Targeting AKT1-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)

  221	GUAUUUUGAUGAGGAGUUCACGGcrnCC
  222	GGCCCAGAUGAUCACCAUCACACcrnCA
  223	GGGAAGAAAACUAUCCUGCGGGUcrnUU
  224	GUUUUAAUUUAUUUCAUCCAGUUcrnUcrnG
  225	ACGUAGGGAAAUGUUAAGGACUUcrnCcrnU

• TABLE 6
  RNA Targeting AKT1-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  226	GGCCGUGAACUCCUCAUCAAAAUACCU
  227	UGGUGUGAUGGUGAUCAUCUGGGCCGU
  228	AAACCCGCAGGAUAGUUUUCUUCCCUA
  229	CAAACUGGAUGAAAUAAAUUAAAACCC
  230	AGAAGUCCUUAACAUUUCCCUACGUGA

• Sequence specific sense strands for an mdRNAs targeting AKT1-1 are shown in Tables 7, 8 and 9. The CRN in Tables 7, 8 and 9 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q.
• In a nicked mdRNA, each one of sequences SEQ ID NOs:231-235 is attached with a nicked bond to one of the nick sequences SEQ ID NOs:236-240, respectively, in other words, SEQ ID NO:231 is attached to SEQ ID NO:236, SEQ ID NO:232 is attached to SEQ ID NO:237, and so forth, to form a nicked sense strand. The corresponding antisense strand is shown in Table 6.
• In a gapped mdRNA, each one of sequences SEQ ID NOs:231-235 is strand 51 while one of the gap sequences SEQ ID NOs:236-240 is strand S2, respectively, in other words, SEQ ID NO:231 is strand 51 and SEQ ID NO:236 is strand S2, SEQ ID NO:232 is strand 51 and SEQ ID NO:237 is strand S2, and so forth. Strands 51 and S2 complex with the corresponding antisense strand of Table 6 to form a gapped structure.

• TABLE 7
  RNA Targeting AKT1-1

  		Nick
  	SEQ ID NO:	position	Sequence (5′ to 3′)
  	231	14	crnGUAUUUUGAUGAGG
  	232	12	GGCCCAGAUGAcrnU
  	233	14	GGGAAGAAAACUAU
  	234	15	crnGUUUUAAUUUAUUUcrnC
  	235	12	crnAcrnCGUAGGGAAAU

• TABLE 8
  RNA Targeting AKT1-1

  SEQ ID NO:	Nick Sequence 1 (5′ to 3′)
  236	AGUUCACGGCcrnC
  237	CACCAUCACACCcrnA
  238	CCUGCGGGUcrnUcrnU
  239	AUCCAGUUUG
  240	GUUAAGGACUUcrnCcrnU

• TABLE 9
  RNA Targeting AKT1-1

  SEQ ID NO:	Gap Sequence 2 (5′ to 3′)
  241	GUUCACGGCcrnC
  242	ACCAUCACACCcrnA
  243	CUGCGGGUcrnUcrnU
  244	UCCAGUUUcrnG
  245	UUAAGGACUUCcrnU

Example 4RNA Targeting b2a2
• Sequence specific RNAs targeting b2a2 are shown in Tables 10 and 11. The CRN in Tables 10 and 11 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:246-250 will complex with one of the antisense sequences SEQ ID NOs:251-255, respectively, in other words, SEQ ID NO:246 will complex with SEQ ID NO:251, SEQ ID NO:247 will complex with SEQ ID NO:252, and so forth.

• TABLE 10
  RNA Targeting b2a2

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  246	crnGCUGCUUAUGUCUCCCAGCAUGGcrnCcrnC
  247	AAGUGUUUCAGAAGCUUCUCCCUcrnGcrnA
  248	GACCAUCAAUAAGGAAGAAGCCCcrnUcrnU
  249	crnCcrnCAUCAAUAAGGAAGAAGCCCUUCA
  250	crnUcrnCAAUAAGGAAGAAGCCCUUCAGCG

• TABLE 11
  RNA Targeting b2a2

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  251	GGCCAUGCUGGGAGACAUAAGCAGCAG
  252	UCAGGGAGAAGCUUCUGAAACACUUCU
  253	AAGGGCUUCUUCCUUAUUGAUGGUCAG
  254	UGAAGGGCUUCUUCCUUAUUGAUGGUC
  255	CGCUGAAGGGCUUCUUCCUUAUUGAUG

Example 5RNA Targeting b3a2
• Sequence specific RNAs targeting b3a2 are shown in Tables 12 and 13. The CRN in Tables 12 and 13 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:256-260 will complex with one of the antisense sequences SEQ ID NOs:261-265, respectively, in other words, SEQ ID NO:256 will complex with SEQ ID NO:261, SEQ ID NO:257 will complex with SEQ ID NO:262, and so forth.

• TABLE 12
  RNA Targeting b3a2

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  256	ACUGGAUUUAAGCAGAGUUCAAAAcrnG
  257	CUGGAUUUAAGCAGAGUUCAAAAGcrnC
  258	GAUUUAAGCAGAGUUCAAAAGCCCcrnU
  259	AUUUAAGCAGAGUUCAAAAGCCCUcrnU
  260	UUAAGCAGAGUUCAAAAGCCCUUCcrnA

• TABLE 13
  RNA Targeting b3a2

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  261	CUUUUGAACUCUGCUUAAAUCCAGUGG
  262	GCUUUUGAACUCUGCUUAAAUCCAGUG
  263	AGGGCUUUUGAACUCUGCUUAAAUCCA
  264	AAGGGCUUUUGAACUCUGCUUAAAUCC
  265	UGAAGGGCUUUUGAACUCUGCUUAAAU

Example 6RNA Targeting EGFR-1
• Sequence specific RNAs targeting EGFR-1 are shown in Tables 14 and 15. The CRN in Tables 14 and 15 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:266-270 will complex with one of the antisense sequences SEQ ID NOs:271-275, respectively, in other words, SEQ ID NO:266 will complex with SEQ ID NO:271, SEQ ID NO:267 will complex with SEQ ID NO:272, and so forth.

• TABLE 14
  RNA Targeting EGFR-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  266	UUCCAGCCCACAUUGGAUUCAUcrnCAG
  267	CAGCUGAGAAUGUGGAAUACCUcrnAAG
  268	AACGUAUCUCCUAAUUUGAGGCcrnUCA
  269	CCUAAAAUAAUUUCUCUACAAUcrnUGG
  270	UGGAAGAUUCAGCUAGUUAGGAcrnGCC

• TABLE 15
  RNA Targeting EGFR-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  271	CUGAUGAAUCCAAUGUGGGCUGGAAUC
  272	CUUAGGUAUUCCACAUUCUCAGCUGUG
  273	UGAGCCUCAAAUUAGGAGAUACGUUUU
  274	CCAAUUGUAGAGAAAUUAUUUUAGGAA
  275	GGCUCCUAACUAGCUGAAUCUUCCAAU

Example 7
• RNA Targeting FLT-1
• Sequence specific RNAs targeting FLT-1 are shown in Tables 16 and 17. The CRN in Tables 16 and 17 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:276-280 will complex with one of the antisense sequences SEQ ID NOs:281-285, respectively, in other words, SEQ ID NO:276 will complex with SEQ ID NO:281, SEQ ID NO:277 will complex with SEQ ID NO:282, and so forth.

• TABLE 16
  RNA Targeting FLT-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  276	crnUGACCUGUGAAGCAACAGUCAAUGcrnG
  277	crnCUAUCUCACACAUCGACAAACCAcrnAU
  278	crnUGUCCUCAAUUGUACUGCUACCACcrnU
  279	AcrnAACCGUAGCUGGCAAGCGGUCUcrnUA
  280	UAcrnGCUGGCAAGCGGUCUUACCGGcrnCU

• TABLE 17
  RNA Targeting FLT-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  281	CCAUUGACUGUUGCUUCACAGGUCAGA
  282	AUUGGUUUGUCGAUGUGUGAGAUAGUU
  283	AGUGGUAGCAGUACAAUUGAGGACAAG
  284	UAAGACCGCUUGCCAGCUACGGUUUCA
  285	AGCCGGUAAGACCGCUUGCCAGCUACG

Example 8RNA Targeting FRAP1
• Sequence specific RNAs targeting FRAP1 are shown in Tables 18 and 19. The CRN in Tables 18 and 19 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:286-290 will complex with one of the antisense sequences SEQ ID NOs:291-295, respectively, in other words, SEQ ID NO:286 will complex with SEQ ID NO:291, SEQ ID NO:287 will complex with SEQ ID NO:292, and so forth.

• TABLE 18
  RNA Targeting FRAP1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  286	ACUUUGGAUGUUCCAACGCAAGUcrnUcrnG
  287	AAUGCUUCCACUAAACUGAAACCcrnAcrnU
  288	GAGAAAGUUUGACUUUGUUAAAUAcrnU
  289	AAAGAACUACUGUAUAUUAAAAGUcrnU
  290	UUAGAAAUACGGGUUUUGACUUAAcrnC

• TABLE 19
  RNA Targeting FRAP1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  291	CAACUUGCGUUGGAACAUCCAAAGUGU
  292	AUGGUUUCAGUUUAGUGGAAGCAUUUA
  293	AUAUUUAACAAAGUCAAACUUUCUCAC
  294	AACUUUUAAUAUACAGUAGUUCUUUUC
  295	GUUAAGUCAAAACCCGUAUUUCUAAAG

Example 9RNA Targeting HIF1A-1
• Sequence specific RNAs targeting HIF1A-1 are shown in Tables 20 and 21. The CRN in Tables 20 and 21 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:296-300 will complex with one of the antisense sequences SEQ ID NOs:301-305, respectively, in other words, SEQ ID NO:296 will complex with SEQ ID NO:301, SEQ ID NO:297 will complex with SEQ ID NO:302, and so forth.

• TABLE 20
  RNA Targeting HIF1A-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  296	CUAGUCCUUCCGAUGGAAcrnGCACUAG
  297	CCAGUGAAUAUUGUUUUcrnUAUGUGGA
  298	AUGAAUUCAAGUUGGAcrnAUUGGUAGA
  299	CAGGACACAGAUUUAcrnGACUUGGAGA
  300	CUCAAAGCACAGUUcrnACAGUAUUCCA

• TABLE 21
  RNA Targeting HIF1A-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  301	CUAGUGCUUCCAUCGGAAGGACUAGGU
  302	UCCACAUAAAAACAAUAUUCACUGGGA
  303	UCUACCAAUUCCAACUUGAAUUCAUUG
  304	UCUCCAAGUCUAAAUCUGUGUCCUGAG
  305	UGGAAUACUGUAACUGUGCUUUGAGGA

Example 10RNA Targeting IL17A
• Sequence specific RNAs targeting IL17A are shown in Tables 22 and 23. The CRN in Tables 22 and 23 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:306-310 will complex with one of the antisense sequences SEQ ID NOs:311-315, respectively, in other words, SEQ ID NO:306 will complex with SEQ ID NO:311, SEQ ID NO:307 will complex with SEQ ID NO:312, and so forth.

• TABLE 22
  RNA Targeting IL17A

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  306	UGAGCUAUUUAAGGAUCUAUUUAUG
  307	AAAAGGUGAAAAAGCACUAUUAUCA
  308	GAAAAAGCACUAUUAUCAGUUCUGC
  309	GGCUGAAAAGAAAGAUUAAACCUAC
  310	UAAACCCUUAUAAUAAAAUCCUUCU

• TABLE 23
  RNA Targeting IL17A

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  311	CAUAAAUAGAUCCUUAAAUAGCUCAAcrnA
  312	UGAUAAUAGUGCUUUUUCACCUUUUUcrnC
  313	GCAGAACUGAUAAUAGUGCUUUUUCAcrnC
  314	GUAGGUUUAAUCUUUCUUUUCAGCCAcrnU
  315	AGAAGGAUUUUAUUAUAAGGGUUUAAcrnU

Example 11RNA Targeting IL18
• Sequence specific RNAs targeting IL18 are shown in Tables 24 and 25. The CRN in Tables 24 and 25 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:316-320 will complex with one of the antisense sequences SEQ ID NOs:321-325, respectively, in other words, SEQ ID NO:316 will complex with SEQ ID NO:321, SEQ ID NO:317 will complex with SEQ ID NO:322, and so forth.

• TABLE 24
  RNA Targeting IL18

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  316	CAGGAAUAAAGAUGGCUGCUGAACcrnC
  317	AAUUUGAAUGACCAAGUUCUCUUCcrnA
  318	AUGUAUAAAGAUAGCCAGCCUAGAcrnG
  319	GGCUGUAACUAUCUCUGUGAAGUGcrnU
  320	UCUGUGAAGUGUGAGAAAAUUUCAcrnA

• TABLE 25
  RNA Targeting IL18

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  321	GGUUCAGCAGCCAUCUUUAUUCCUGCG
  322	UGAAGAGAACUUGGUCAUUCAAAUUUC
  323	CUCUAGGCUGGCUAUCUUUAUACAUAC
  324	ACACUUCACAGAGAUAGUUACAGCCAU
  325	UUGAAAUUUUCUCACACUUCACAGAGA

Example 12RNA Targeting IL6
• Sequence specific RNAs targeting IL6 are shown in Tables 26 and 27. The CRN in Tables 26 and 27 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:326-330 will complex with one of the antisense sequences SEQ ID NOs:331-335, respectively, in other words, SEQ ID NO:326 will complex with SEQ ID NO:331, SEQ ID NO:327 will complex with SEQ ID NO:332, and so forth.

• TABLE 26
  RNA Targeting IL6

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  326	ACGAAAGAGAAGCUCUAUCUcrnCGCCU
  327	CUCCACAAGCGCCUUCGGUCCcrnAGUU
  328	GAGAAGAUUCCAAAGAUGUAGCcrnCGC
  329	AAUCUGGAUUCAAUGAGGAGACUcrnUG
  330	AGAACAGAUUUGAGAGUAGUGAGGcrnA

• TABLE 27
  RNA Targeting IL6

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  331	AGGCGAGAUAGAGCUUCUCUUUCGUUC
  332	AACUGGACCGAAGGCGCUUGUGGAGAA
  333	GCGGCUACAUCUUUGGAAUCUUCUCCU
  334	CAAGUCUCCUCAUUGAAUCCAGAUUGG
  335	UCCUCACUACUCUCAAAUCUGUUCUGG

Example 13RNA Targeting MAP2K1
• Sequence specific RNAs targeting MAP2K1 are shown in Tables 28 and 29. The CRN in Tables 28 and 29 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:336-340 will complex with one of the antisense sequences SEQ ID NOs:341-345, respectively, in other words, SEQ ID NO:336 will complex with SEQ ID NO:341, SEQ ID NO:337 will complex with SEQ ID NO:342, and so forth.

• TABLE 28
  RNA Targeting MAP2K1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  336	crnCcrnAcrnUcrnGcrnCcrnUcrnGcrnCcrnUcrnGGCGUCUAAGUGUUUG
  337	crnAcrnGcrnAcrnUcrnGUGCAUUUCACCUGUGACAAA
  338	crnUcrnCcrnAAAACCUGUGCCAGGCUGAAUUA
  339	crnGcrnAAUGUGGGUAGUCAUUCUUACAAU
  340	crnAUGUGGGUAGUCAUUCUUACAAUUG

• TABLE 29
  RNA Targeting MAP2K1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  341	CAAACACUUAGACGCCAGCAGCAUGGG
  342	UUUGUCACAGGUGAAAUGCACAUCUGA
  343	UAAUUCAGCCUGGCACAGGUUUUGAUC
  344	AUUGUAAGAAUGACUACCCACAUUCAC
  345	CAAUUGUAAGAAUGACUACCCACAUUC

Example 14RNA Targeting MAPK1
• Sequence specific RNAs targeting MAPK1 are shown in Tables 30 and 31. The CRN in Tables 30 and 31 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:346-350 will complex with one of the antisense sequences SEQ ID NOs:351-355, respectively, in other words, SEQ ID NO:346 will complex with SEQ ID NO:351, SEQ ID NO:347 will complex with SEQ ID NO:352, and so forth.

• TABLE 30
  RNA Targeting MAPK1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  346	CAcrnUAcrnUCcrnCUcrnUGcrnGCcrnUAcrnCUcrnAAcrnCAcrnUCcrnUGcrnG
  347	UACcrnUAAcrnCAUcrnCUGcrnGAGcrnACUcrnGUGcrnAGCcrnU
  348	CAUAcrnAGUUcrnGUGUcrnGCUUcrnUUUAcrnUUAAcrnU
  349	GCAUCcrnAUUUUcrnGGCUCcrnUUCUUcrnACAUU
  350	GCUCUUcrnCUUACAcrnUUUGUAcrnAAAAUGcrnU

• TABLE 31
  RNA Targeting MAPK1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  351	CCAGAUGUUAGUAGCCAAGGAUAUGGU
  352	AGCUCACAGUCUCCAGAUGUUAGUAGC
  353	AUUAAUAAAAAGCACACAACUUAUGGC
  354	AAUGUAAGAAGAGCCAAAAUGAUGCAU
  355	ACAUUUUUACAAAUGUAAGAAGAGCCA

Example 15RNA Targeting MAPK14-1
• Sequence specific RNAs targeting MAPK14-1 are shown in Tables 32 and 33. The CRN in Tables 32 and 33 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:356-360 will complex with one of the antisense sequences SEQ ID NOs:361-365, respectively, in other words, SEQ ID NO:356 will complex with SEQ ID NO:361, SEQ ID NO:357 will complex with SEQ ID NO:362, and so forth.

• TABLE 32
  RNA Targeting MAPK14-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  356	UCGGAAAcrnCAAGUUAUUCUCUUCACU
  357	ACUCCCAAcrnUAACUAAUGCUAAGAAA
  358	AAUGCUAAGcrnAAAUGCUGAAAAUCAA
  359	crnGUCUUUCUCUAAAUAUGAUUACUUU
  360	crnUGAAUUUCAGGCAUUUUGUUCUACA

• TABLE 33
  RNA Targeting MAPK14-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  361	AGUGAAGAGAAUAACUUGUUUCCGAAG
  362	UUUCUUAGCAUUAGUUAUUGGGAGUGA
  363	UUGAUUUUCAGCAUUUCUUAGCAUUAG
  364	AAAGUAAUCAUAUUUAGAGAAAGACAG
  365	UGUAGAACAAAAUGCCUGAAAUUCAGC

Example 16RNA Targeting PDGFA
• Sequence specific RNAs targeting PDGFA are shown in Tables 34 and 35. The CRN in Tables 34 and 35 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:366-370 will complex with one of the antisense sequences SEQ ID NOs:371-375, respectively, in other words, SEQ ID NO:366 will complex with SEQ ID NO:371, SEQ ID NO:367 will complex with SEQ ID NO:372, and so forth.

• TABLE 34
  RNA Targeting PDGFA

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  366	AAUGUGACAUCAAAGCAAGUAUUGcrnU
  367	CAUCAAAGCAAGUAUUGUAGCACUcrnC
  368	AGAGAGAGAAAACAAAACCACAAAcrnU
  369	UCGCUGUAGUAUUUAAGCCCAUACcrnA
  370	CGCUGUAGUAUUUAAGCCCAUACAcrnG

• TABLE 35
  RNA Targeting PDGFA

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  371	ACAAUACUUGCUUUGAUGUCACAUUAA
  372	GAGUGCUACAAUACUUGCUUUGAUGUC
  373	AUUUGUGGUUUUGUUUUCUCUCUCUCU
  374	UGUAUGGGCUUAAAUACUACAGCGAGG
  375	CUGUAUGGGCUUAAAUACUACAGCGAG

Example 17RNA Targeting PDGFRA
• Sequence specific RNAs targeting PDGFRA are shown in Tables 36 and 37. The CRN in Tables 36 and 37 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:376-380 will complex with one of the antisense sequences SEQ ID NOs:381-385, respectively, in other words, SEQ ID NO:376 will complex with SEQ ID NO:381, SEQ ID NO:377 will complex with SEQ ID NO:382, and so forth.

• TABLE 36
  RNA Targeting PDGFRA

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  376	crnCcrnUcrnGUUCUGAUCGGCCAGUUUUCGGA
  377	crnAcrnAcrnAUAAUUUGAACUUUGGAACAGGG
  378	crnUGCGACCUUAAUUUAACUUUCCAGU
  379	crnCUGAGAAAGCUAAAGUUUGGUUUUG
  380	crnAGUAAAGAUGCUACUUCCCACUGUA

• TABLE 37
  RNA Targeting PDGFRA

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  381	UCCGAAAACUGGCCGAUCAGAACAGCC
  382	CCCUGUUCCAAAGUUCAAAUUAUUUGU
  383	ACUGGAAAGUUAAAUUAAGGUCGCAAU
  384	CAAAACCAAACUUUAGCUUUCUCAGCC
  385	UACAGUGGGAAGUAGCAUCUUUACUUU

Example 18RNA Targeting PDGFRA
• Sequence specific RNAs targeting PDGFRA are shown in Tables 38 and 39. The CRN in Tables 38 and 39 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:386-390 will complex with one of the antisense sequences SEQ ID NOs:391-395, respectively, in other words, SEQ ID NO:386 will complex with SEQ ID NO:391, SEQ ID NO:387 will complex with SEQ ID NO:392, and so forth.

• TABLE 38
  RNA Targeting PDGFRA

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  386	CUGUUCUGAUCGGCCAGUUUUCcrnGGA
  387	AAAUAAUUUGAACUUUGGAACAGcrnGG
  388	UGCGACCUUAAUUUAACUUUCCAGcrnU
  389	crnCUGAGAAAcrnGCUAAAGUUUGGUUUUcrnG
  390	crnAGUAAAGAUcrnGCUACUUCCCACUGcrnUA

• TABLE 39
  RNA Targeting PDGFRA

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  391	UCCGAAAACUGGCCGAUCAGAACAGCC
  392	CCCUGUUCCAAAGUUCAAAUUAUUUGU
  393	ACUGGAAAGUUAAAUUAAGGUCGCAAU
  394	CAAAACCAAACUUUAGCUUUCUCAGCC
  395	UACAGUGGGAAGUAGCAUCUUUACUUU

Example 19RNA Targeting PIK3CA
• Sequence specific RNAs targeting PIK3CA are shown in Tables 40 and 41. The CRN in Tables 40 and 41 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:396-400 will complex with one of the antisense sequences SEQ ID NOs:401-405, respectively, in other words, SEQ ID NO:396 will complex with SEQ ID NO:401, SEQ ID NO:397 will complex with SEQ ID NO:402, and so forth.

• TABLE 40
  RNA Targeting PIK3CA

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  396	crnGAAUCCUAGUAGAAUGUUUACUACC
  397	GAAAGGGcrnAAGAAUUUUUUGAUGAAA
  398	UAUCGGCAcrnUGCCAGUGUGUGAAUUU
  399	CACCUCAUcrnAcrnGUAGAGCAAUGUAUGU
  400	CCAGAAUcrnUcrnGcrnCCAAAGCACAUAUAUA

• TABLE 41
  RNA Targeting PIK3CA

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  401	GGUAGUAAACAUUCUACUAGGAUUCUU
  402	UUUCAUCAAAAAAUUCUUCCCUUUCUG
  403	AAAUUCACACACUGGCAUGCCGAUAGC
  404	ACAUACAUUGCUCUACUAUGAGGUGAA
  405	UAUAUAUGUGCUUUGGCAAUUCUGGUG

Example 20RNA Targeting PKN3
• Sequence specific RNAs targeting PKN3 are shown in Tables 42 and 43. The CRN in Tables 42 and 43 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:406-410 will complex with one of the antisense sequences SEQ ID NOs:411-415, respectively, in other words, SEQ ID NO:406 will complex with SEQ ID NO:411, SEQ ID NO:407 will complex with SEQ ID NO:412, and so forth.

• TABLE 42
  RNA Targeting PKN3

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  406	UGCAGUUCUUACACGAGAAGAAGAcrnU
  407	ACGAGAAGAAGAUCAUUUACAGcrnGGA
  408	CGAcrnGAAGAAGAUCAUUUACAGGGAC
  409	AAGAAGAUcrnCAUUUACAGGGACCUGA
  410	AGAGGAAGAGGUGUUUGACUGCAUC

• TABLE 43
  RNA Targeting PKN3

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  411	AUCUUCUUCUCGUGUAAGAACUGCAGC
  412	UCCCUGUAAAUGAUCUUCUUCUCGUGU
  413	GUCCCUGUAAAUGAUCUUCUUCUCGUG
  414	UCAGGUCCCUGUAAAUGAUCUUCUUCU
  415	GAUGCAGUCAAACACCUCUUCCUCUGU

Example 21RNA Targeting RAF1
• Sequence specific RNAs targeting RAF1 are shown in Tables 44 and 45. The CRN in Tables 44 and 45 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:416-420 will complex with one of the antisense sequences SEQ ID NOs:421-425, respectively, in other words, SEQ ID NO:416 will complex with SEQ ID NO:421, SEQ ID NO:417 will complex with SEQ ID NO:422, and so forth.

• TABLE 44
  RNA Targeting RAF1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  416	UGCAGUAAAcrnGAUCCUAAAGGUUGUC
  417	AGUAAAGAcrnUCCUAAAGGUUGUCGAC
  418	UGACAAAGGAcrnCAACCUGGCAAUUGU
  419	GCAAUUGUGACCCAGUGGUGCGAGcrnG
  420	crnAACAUCAUCCAUAGAGACAUGAAAU

• TABLE 45
  RNA Targeting RAF1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  421	GACAACCUUUAGGAUCUUUACUGCAAC
  422	GUCGACAACCUUUAGGAUCUUUACUGC
  423	ACAAUUGCCAGGUUGUCCUUUGUCAUG
  424	CCUCGCACCACUGGGUCACAAUUGCCA
  425	AUUUCAUGUCUCUAUGGAUGAUGUUCU

Example 22RNA Targeting SRD5A1
• Sequence specific RNAs targeting SRD5A1 are shown in Tables 46 and 47. The CRN in Tables 46 and 47 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:426-430 will complex with one of the antisense sequences SEQ ID NOs:431-435, respectively, in other words, SEQ ID NO:426 will complex with SEQ ID NO:431, SEQ ID NO:427 will complex with SEQ ID NO:432, and so forth.

• TABLE 46
  RNA Targeting SRD5A1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  426	AAUGGAGGUUGAAUAUCCUACUGUcrnG
  427	GGAGGUUGAAUAUCCUACUGUGUcrnAA
  428	AUUUUGAGUUUUCCCUUGUAGUcrnGUA
  429	crnUAUCCUGUUUGUUCUUUGUUGAUUG
  430	CcrnCUGUUUGUUCUUUGUUGAUUGAAA

• TABLE 47
  RNA Targeting SRD5A1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  431	CACAGUAGGAUAUUCAACCUCCAUUUC
  432	UUACACAGUAGGAUAUUCAACCUCCAU
  433	UACACUACAAGGGAAAACUCAAAAUCU
  434	CAAUCAACAAAGAACAAACAGGAUAAA
  435	UUUCAAUCAACAAAGAACAAACAGGAU

Example 23RNA Targeting TNF
• Sequence specific RNAs targeting TNF are shown in Tables 48 and 49. The CRN in Tables 48 and 49 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:436-440 will complex with one of the antisense sequences SEQ ID NOs:441-445, respectively, in other words, SEQ ID NO:436 will complex with SEQ ID NO:441, SEQ ID NO:437 will complex with SEQ ID NO:442, and so forth.

• TABLE 48
  RNA Targeting TNF

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  436	crnAAGAGGGAGAGAAGCAACUACAGAC
  437	CGUCUCCUACCAGACCAAGGUCAcrnAC
  438	GAUCAAUCGcrnGCCCGACUAUCUCGAC
  439	GGACGAACAcrnUCCAACCUUCCCAAAC
  440	AGGGUCGGAcrnACCCAAGCUUAGAACU

• TABLE 49
  RNA Targeting TNF

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  441	GUCUGUAGUUGCUUCUCUCCCUCUUAG
  442	GUUGACCUUGGUCUGGUAGGAGACGGC
  443	GUCGAGAUAGUCGGGCCGAUUGAUCUC
  444	GUUUGGGAAGGUUGGAUGUUCGUCCUC
  445	AGUUCUAAGCUUGGGUUCCGACCCUAA

Example 24RNA Targeting TNFSF13B
• Sequence specific RNAs targeting TNFSF13B are shown in Tables 50 and 51. The CRN in Tables 50 and 51 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:446-450 will complex with one of the antisense sequences SEQ ID NOs:451-455, respectively, in other words, SEQ ID NO:446 will complex with SEQ ID NO:451, SEQ ID NO:447 will complex with SEQ ID NO:452, and so forth.

• TABLE 50
  RNA Targeting TNFSF13B

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  446	AAACACAGAUAACAGGAAAUGAUCC
  447	CUUAAGAAAAGAGAAGAAAUGAAAC
  448	CUGAAGGAGUGUGUUUCCAUCCUCC
  449	UCACCGCGGGACUGAAAAUCUUUGA
  450	AGCAGAAAUAAGCGUGCCGUUCAGG

• TABLE 51
  RNA Targeting TNFSF13B

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  451	crnGGAUCAUUUCCUGUUAUCUGUGUUUGU
  452	crnGUUUCAUUUCUUCUCUUUUCUUAAGGC
  453	GcrnGAGGAUGGAAACACACUCCUUCAGUU
  454	UcrnCAAAGAUUUUCAGUCCCGCGGUGACA
  455	CCcrnUGAACGGCACGCUUAUUUCUGCUGU

Example 25RNA Targeting VEGFA-1
• Sequence specific RNAs targeting VEGFA-1 are shown in Tables 52 and 53. The CRN in Tables 52 and 53 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:456-460 will complex with one of the antisense sequences SEQ ID NOs:461-465, respectively, in other words, SEQ ID NO:456 will complex with SEQ ID NO:461, SEQ ID NO:457 will complex with SEQ ID NO:462, and so forth.

• TABLE 52
  RNA Targeting VEGFA-1

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  456	CAAAGAAAGAUAGAGCAAGACAAGcrnA
  457	AAGAAAGAUAGAGCAAGACAAGAcrnAA
  458	GAAAGCAUUUGUUUGUACAAGAcrnUCC
  459	UGAGUUAAACGAACGUACUUGCcrnAcrnGA
  460	ACUGAUACAGAACGAUCGAUACcrnAcrnGcrnA

• TABLE 53
  RNA Targeting VEGFA-1

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  461	UCUUGUCUUGCUCUAUCUUUCUUUGGU
  462	UUUCUUGUCUUGCUCUAUCUUUCUUUG
  463	GGAUCUUGUACAAACAAAUGCUUUCUC
  464	UCUGCAAGUACGUUCGUUUAACUCAAG
  465	UCUGUAUCGAUCGUUCUGUAUCAGUCU

Example 26Increased Melting Temperature of a CRN-Containing Duplex
• A CRN-containing RNA duplex targeted to ApoB (SEQ ID NOs:468-469) was prepared and its melting temperature was compared to the same RNA duplex targeted to ApoB that did not contain the CRN (SEQ ID NOs:466-467). The CRN used in this experiment was crnU.

• 	ApoB
  	Passenger Strand:
  	(SEQ ID NO: 466)
  	5′-CAUCACACUGAAUACCAAUTT
  	Guide Strand:
  	(SEQ ID NO: 467)
  	5′-AUUGGUAUUCAGUGUGAUGTT
  	CRN-ApoB
  	Passenger Strand:
  	(SEQ ID NO: 468)
  	5′-CAUCACACcrnUGAAUACCAAUTT
  	Guide Strand:
  	(SEQ ID NO: 469)
  	5′-AUUGGUAUUCAGUGUGAUGTT

• The CRN-containing RNA duplex targeted to ApoB (SEQ ID NOs:468-469) had a melting temperature of 68.5° C., while the same RNA duplex targeted to ApoB that did not contain the CRN had a melting temperature of 67.1° C. Thus, the use of a single conformationally restricted nucleomonomer crnU increased the melting temperature of the duplex by 1.4° C.
• A CRN-containing RNA duplex test sequence (SEQ ID NOs:472-473) was prepared and its melting temperature was compared to the same RNA duplex test sequence that did not contain the CRN (SEQ ID NOs:470-471). The CRN used in this experiment was crnU.

• 	Test Sequence
  	Passenger Strand:
  	(SEQ ID NO: 470)
  	5′-UUGUUGUUGUUGUUGUUGU
  	Guide Strand:
  	(SEQ ID NO: 471)
  	5′-ACAACAACAACAACAACAA
  	CRN-Test Sequence
  	Passenger Strand:
  	(SEQ ID NO: 472)
  	5′-UUGUUGUcrnUGUUGUUGUUGU
  	Guide Strand:
  	(SEQ ID NO: 473)
  	5′-ACAACAACAACAACAACAA

• The CRN-containing RNA duplex test sequence had a melting temperature of 63.6° C., while the same RNA duplex test sequence that did not contain the CRN had a melting temperature of 59.8° C. Thus, the use of a single conformationally restricted nucleomonomer crnU increased the melting temperature of the test sequence RNA duplex by 3.8° C.
Example 27RNA Targeting Factor VII
• Sequence specific RNAs targeting Factor VII are shown in Tables 54 and 55. The CRN in Tables 54 and 55 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:474-484 will complex with one of the antisense sequences SEQ ID NOs:485-495, respectively, in other words, SEQ ID NO:474 will complex with SEQ ID NO:485, SEQ ID NO:475 will complex with SEQ ID NO:486, and so forth. The designation “unaU” refers to an hydroxymethyl substituted nucleomonomer (unlocked nucleomonomer, UNA) having a U nucleobase. The designation “mU” refers to modified nucleotide “um” which is 2′-O-methyluridine.

• TABLE 54
  RNA Targeting Factor VII

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  474	CCAUGUGGAAAAAUACCUAcrnUmU
  475	CUGGAUUUCUUACAGUGAUmUcrnU
  476	AGUGGCUGCAAAAGCUCAUcrnUcrnU
  477	crnGGCAGGUCCUGUUGUUGGUmUmU
  478	CcrnCAGGGUCUCCCAGUACAUmUmU
  479	crnUcrnCGAGUGGCUGCAAAAGCUmUmU
  480	crnGCcrnGGCUGUGAGCAGUACUGmUmU
  481	crnAGGAUGAcrnCCAGCUGAUCUGmUmU
  482	crnCGAUGCUGACUCCAUGUGUmUmU
  483	crnGGCGGUUGUUUAGCUCUCAmUmU
  484	crnUGUCUUGGUUUCAAUUAAAunaUunaU

• TABLE 55
  RNA Targeting Factor VII

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  485	UAGGUAUUUUUCCACAUGGmUmU
  486	AUCACUGUAAGAAAUCCAGmUmU
  487	AUGAGCUUUUGCAGCCACUmUmU
  488	ACCAACAACAGGACCUGCCmUmU
  489	AUGUACUGGGAGACCCUGGmUmU
  490	AGCUUUUGCAGCCACUCGAmUmU
  491	CAGUACUGCUCACAGCCGCmUmU
  492	CAGAUCAGCUGGUCAUCCUmUmU
  493	ACACAUGGAGUCAGCAUCGmUmU
  494	UGAGAGCUAAACAACCGCCmUmU
  495	UUUAAUUGAAACCAAGACAunaUunaU

Example 28RNA Targeting ApoB
• Sequence specific RNAs targeting ApoB are shown in Tables 56 and 57. The CRN in Tables 56 and 57 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:496-501 will complex with one of the antisense sequences SEQ ID NOs:502-507, respectively, in other words, SEQ ID NO:496 will complex with SEQ ID NO:502, SEQ ID NO:497 will complex with SEQ ID NO:503, and so forth.

• TABLE 56
  RNA Targeting ApoB

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  496	GGACAUUCAGAACAAGAAAUcrnU
  497	ACAGAGUCCCUCAAACAGAcrnUU
  498	CAUCACACUGAAUACCAAUcrnUcrnU
  499	AAGGGAAUCUUAUAUUUGAUCCAcrnAcrnA
  500	crnACAGAGUCCCUCAAACAGACAUGAC
  501	GcrnUCUCAAAAGGUUUACUAAUAUUCcrnG

• TABLE 57
  RNA Targeting ApoB

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  502	UUUCUUGUUCUGAAUGUCCUU
  503	UCUGUUUGAGGGACUCUGUUU
  504	AUUGGUAUUCAGUGUGAUGUU
  505	UUUGGAUCAAAUAUAAGAUUCCCUUCU
  506	GUCAUGUCUGUUUGAGGGACUCUGUGA
  507	CGAAUAUUAGUAAACCUUUUGAGACUG

Example 29RNA Targeting TTR
• Sequence specific RNAs targeting TTR are shown in Tables 58 and 59. The CRN in Tables 58 and 59 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:508-512 will complex with one of the antisense sequences SEQ ID NOs:513-517, respectively, in other words, SEQ ID NO:508 will complex with SEQ ID NO:513, SEQ ID NO:509 will complex with SEQ ID NO:514, and so forth.

• TABLE 58
  RNA Targeting TTR

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  508	GUCCUCUGAUGGUCAAAGUUcrnU
  509	GACUGGUAUUUGUGUCUGAUcrnU
  510	UGGACUGGUAUUUGUGUCUUcrnU
  511	CACUCAUUCUUGGCAGGAUUcrnU
  512	CCUUGCUGGACUGGUAUUUUU

• TABLE 59
  RNA Targeting TTR

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  513	ACUUUGACCAUCAGAGGACUU
  514	UCAGACACAAAUACCAGUCUU
  515	AGACACAAAUACCAGUCCAUU
  516	AUCCUGCCAAGAAUGAGUGUU
  517	AAAUACCAGUCCAGCAAGGUU

Example 30RNA Targeting DGAT2
• Sequence specific RNAs targeting DGAT2 are shown in Tables 60 and 61. The CRN in Tables 60 and 61 is based on Monomer R, Monomer Q, or a combination of Monomers R and Q. Each one of sense sequences SEQ ID NOs:518-522 will complex with one of the antisense sequences SEQ ID NOs:523-527, respectively, in other words, SEQ ID NO:518 will complex with SEQ ID NO:523, SEQ ID NO:519 will complex with SEQ ID NO:524, and so forth.

• TABLE 60
  RNA Targeting DGAT2

  SEQ ID NO:	Sense Sequence (5′ to 3′)
  518	crnUCUCUGUCACCUGGCUCAAUAGGdTdC
  519	CcrnGAGACUACUUUCCCAUCCAGCUdGdG
  520	GAcrnAGACACACAACCUGCUGACCAdCdC
  521	UGAcrnCCACCAGGAACUAUAUCUUUdGdG
  522	GACcrnCACcrnCAGcrnGAACUAUAUCUUUGdGdA

• TABLE 61
  RNA Targeting DGAT2

  SEQ ID NO:	Antisense Sequence (5′ to 3′)
  523	GACCUAUUGAGCCAGGUGACAGAGAAG
  524	CCAGCUGGAUGGGAAAGUAGUCUCGAA
  525	GGUGGUCAGCAGGUUGUGUGUCUUCAC
  526	CCAAAGAUAUAGUUCCUGGUGGUCAGC
  527	UCCAAAGAUAUAGUUCCUGGUGGUCAG

Claims (31)

1. A nucleic acid compound comprising a first strand having from 10 to 60 nucleomonomers, wherein from 1 to 45 of the nucleomonomers of the first strand are the same or different conformationally restricted nucleomonomers each independently selected from

Monomer R having the formula:

wherein X is independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF or CF₂;

R₂and R₃are phosphodiester linkages of the nucleic acid compound; and

B is a nucleobase or nucleobase analog; and

Monomer Q having the formula:

wherein X and Y are independently for each occurrence selected from O, S, CH₂, C═O, C═S, C═CH₂, CHF, CF₂;

Z is independently for each occurrence selected from N or CH;

R₂is independently for each occurrence selected from hydrogen, —F, —OH, —OCH₃, —OCH₃OCH₃, —OCH₂CH₃OCH₃, —CH₂CH₃OCH₃, —CH(OCH₃)CH₃, allyl;

R₁and R₃are phosphodiester linkages of the nucleic acid compound; and

B is a nucleobase or nucleobase analog;

wherein each nucleobase or nucleobase analog in the strand is independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O⁶-methylguanine, N⁶-methyladenine, O⁴-methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and any existing deoxy analogs of the foregoing.

2. The compound ofclaim 1, wherein the compound contains two or more of the same or different Monomer R.

3. The compound ofclaim 1, wherein the compound contains two or more of the same or different Monomer Q.

4. The compound ofclaim 1, wherein the first strand has from 19 to 27 nucleomonomers.

5. The compound ofclaim 1, wherein the nucleic acid is RNA.

6. The compound ofclaim 1, wherein the nucleic acid is RNA and DNA.

7. The compound ofclaim 1, further comprising one or more hydroxymethyl substituted nucleomonomers.

8. The compound ofclaim 1, further comprising one or two additional strands each having from 7 to 60 nucleomonomers, wherein at least a portion of each of the additional strands is complementary to a portion of the first strand, wherein the first strand and the one or two additional complementary strands can anneal to form one or more duplex portions having a total of from 8 to 60 base pairs in the duplex portions, and wherein one or more of the nucleomonomers of the one or two additional strands is a conformationally restricted nucleomonomer.

9. The compound ofclaim 8, wherein any one or more of the strands includes a sequence for PLK1 selected from SEQ ID NOs:161-220.

10. The compound ofclaim 8, wherein any one or more of the strands includes a sequence for Survivin BIRC5 selected from SEQ ID NOs:1-160.

11. The compound ofclaim 8, wherein any one or more of the strands includes a sequence for Factor VII selected from SEQ ID NOs:474-495.

12. The compound ofclaim 8, wherein any one or more of the strands includes a sequence for ApoB selected from SEQ ID NOs:496-507.

13. The compound ofclaim 8, wherein any one or more of the strands includes a sequence selected from SEQ ID NOs:221-230, 231-245, 246-255, 256-265, 266-275, 276-285, 286-295, 296-305, 306-315, 316-325, 326-335, 336-345, 346-355, 356-365, 366-375, 376-385, 386-395, 396-405, 406-415, 416-425, 426-435, 436-445, 446-455, 456-465, 508-517, and 518-527.

14. The compound ofclaim 8, wherein the conformationally restricted nucleomonomers are only present in either of the one or more additional strands, and the first strand does not contain any conformationally restricted nucleomonomers.

15. The compound ofclaim 8, wherein the melting temperature of the compound is increased by at least 1° C. over the same compound that does not contain any conformationally restricted nucleomonomers.

16. The compound ofclaim 8, wherein the compound is an siRNA.

17. The compound ofclaim 8, wherein the compound is an mdRNA.

18. The compound ofclaim 8, wherein the compound is RNA and DNA.

19. The compound ofclaim 8, wherein one of the additional strands has one or more nicks.

20. The compound ofclaim 8, wherein the compound has one or more duplex gaps that are each independently from 1 to 10 unpaired nucleomonomers in length.

21. The compound ofclaim 8, wherein the compound has a blunt end.

22. The compound ofclaim 8, wherein the compound has a 3′-end overhang.

23. The compound ofclaim 8, further comprising one or more hydroxymethyl substituted nucleomonomers.

24. The compound according toclaim 1 for use in delivering an RNA agent into a cell or an organism.

25. The compound according toclaim 1 for use in mediating nucleic acid modification of a target nucleic acid in a cell or an organism.

26. The compound according toclaim 1 for use in decreasing expression levels of a target mRNA in a cell or an organism.

27. The compound according toclaim 1 for use in inhibiting an endogenous nucleic acid-based regulatory system in a cell or an organism.

28. The compound according toclaim 1 for use in gene regulation, gene analysis, or RNA interference.

29. The compound according toclaim 1 for use in the manufacture of a medicament for a therapeutic target, including targets for cancers, metabolic diseases, inflammatory diseases, and viral infections.

30. The compound according toclaim 1 for use in treating a disease, condition or disorder, including cancers, metabolic diseases, inflammatory diseases, and viral infections.

31. A method for treating a disease, condition or disorder in a subject including cancers, metabolic diseases, inflammatory diseases, and viral infections, the method comprising administering to the subject a compound according toclaim 1.

Images